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ABSTRACT
Mohapatra, Ankita. Ph.D. The University of Memphis. April, 2018. Multiple Stimuli Responsive
Drug Delivery System Based on Magnetic Nanoparticle Embedded Chitosan Microbeads. Major
Professor: Dr Bashir I. Morshed
Direct drug administration has several shortcomings such as low circulation concentration
due to rapid flushing by the immune system, non-specificity to target tissue and inefficient
delivery to avascular sites. A widely adopted solution to these limitations is to sterically shield
the drug from a harsh in vivo environment by encapsulation in a biocompatible, bio-degradable
substrate. These Drug Delivery System (DDS) can be localized at the site and release drug
gradually until the drug reserve is exhausted. However, the efficiency of this DDS can be further
enhanced by designing them to elute drug in response to an external stimulus. This enhancement
would enable a healthcare provider to customize therapeutic profiles from the same DDS
according to the clinical needs of the patient, without repeated invasive procedures or stronger
dosages to maintain potent drug concentration.
Our work explored a chitosan based DDS in the form of microbeads which was successfully
shown to be responsive to both magnetic and electric stimuli. Chitosan was chosen because it is
biodegradable, biocompatible, non-cytotoxic, and has high drug loadability. Magnetic
Nanoaparticles (MNP) were added in the chitosan matrix to facilitate stimulus response. Over the
course of this research, several cross-linkers like poly-ethylene glycol dimethacrylate
(PEGDMA) and glyoxal were tested, and the microbeads loaded with different antibiotics like
tetracycline, vancomycin, etc. The current formulation is chitosan/MNP cross-linked with
PEGDMA and carrying vancomycin as the drug molecule of interest. The average size
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distribution of microbeads with this composition was measured at 288.4 ± 62.2 µm, with the
embedded MNP sized at 10.89 ± 2.67 nm.
A MagneTherm (nanoTherics, UK) was used to provide magnetic stimuli of 25mT at 109.9
kHz to the DDS for 30 mins. Tests conducted in vitro suggested that the DDS was capable of
burst-releasing higher amount of drugs on multiple instances of stimuli, separated from each
other by several hours (short term study) or even several days (long term study). In a long term
study spanning 16 days, magnetic hyperthermia was able to boost vancomycin elution above
minimum inhibitory concentration even after 15 days of continuous elution in vitro. It was also
observed to be non-responsive to normal temperature elevation (general hyperthermia),
indicating that drug elution will not be impacted by in vivo fluctuations in temperature.
Our preliminary study using electric stimuli to cause drug delivery was performed with
electrodes inside Surface Acoustic Wave (SAW) resonators. The statistically significant drug
release compared to non-stimulated samples established DDS sensitivity to electric stimuli and
laid the groundwork for designing our custom Inter-Digitated Electrodes (IDEs) with a larger
scale on a flexible substrate. We printed IDEs with an Inkjet Materials Printer (DMP 2831,
Fujifilm, USA) to apply short bursts of electric pulses of 100 Hz for several seconds to the DDS,
and caused a subsequent higher release of vancomycin. These IDEs have an overall dimension of
18.7 mm x 35 mm. The printed electrodes were < 2 µm in height, and were printed by depositing
Silver nanoparticle ink (40% loading) on a Polyimide substrate (1 mil thickness). Results
demonstrated statistically significant drug release for 3 mins of stimulation.
The results showed that both electric and magnetic stimuli can be used to control drug
discharge from the chitosan DDS. The platform can be easily customized according to the site of
implant and desired dosage profile. The DDS allows multiple stimuli, which can be used
v

independently or in conjunction. The health-provider can choose suitable stimulus to repeatedly
administer drug dosage non-invasively when required, leading to enhanced patient recovery and
compliance.
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PREFACE
This dissertation is in presented in three journal articles format. I am the first author of all of
them.
Article 1 is titled “Stealth Engineering for In Vivo Drug Delivery Systems” is listed as
Chapter 2 and has been published in Critical Reviews in Biomedical Engineering and available
online with the citation: A. Mohapatra, B. I. Moshed, W. O. Haggard., R. A. Smith, “Stealth
Engineering for In Vivo Drug Delivery Systems”, Crit. Rev. Biomed. Eng., 43(5-6), 2015
Article 2 is titled “Magnetic stimulus responsive vancomycin drug delivery system based on
chitosan microbeads embedded with magnetic nanoparticles” is listed as Chapter 3 and has been
published in Journal of Biomedical Materials Research Part B: Applied Biomaterials and is
available online with the citation: A. Mohapatra, M. A. Harris, D. Levine, M. Ghimire, J. A.
Jennings, B. I. Morshed, W. O. Haggard, J. D. Bumgardner, S. R. Mishra, T. Fujiwara,
“Magnetic stimulus responsive vancomycin drug delivery system based on chitosan microbeads
embedded with magnetic nanoparticles”, J. Biomed. Mater. Res. B Appl. Biomater., 2017
Article 3 is titled “Electric Stimulus Responsive Chitosan/MNP Microbeads for a Smart Drug
Delivery System”, and is ready for submission to IEEE Transactions on Biomedical Engineering
in April 2018.
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Chapter 1
INTRODUCTION
1.1 OVERVIEW
Systemic drug administration faces several deterrent factors like rapid opsonisation and
flushing out of circulation [1]. They also tend to have very low target specificity, thus requiring
dosages to be repeated at high concentrations to maintain therapeutic levels needed for treatment.
A Drug Delivery System (DDS) can be described as a vehicle to carry the drug to the target site,
while protecting it from opsonization by the immune system. The DDS is biocompatible,
biodegradable and enhances the lifetime of the drug, thereby ensuring longer bioavailability with
potent concentration at the intended tissue site [2-4].
Although these DDS prolong the drug efficiency, they are characterized by a first-order
release profile until the drug is exhausted [5]. To further allow control and flexibility over the
treatment method, some of these DDS have been modified to be sensitive to a stimulus and
release a higher drug amount as a response when stimulated (Fig. 1.1). The stimulus type may be
external (e.g. magnetic field, electric field, ultrasound) or internal (e.g. pH, temperature).

Fig. 1.1: Conceptualized framework for a DDS responsive to external stimuli
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This work describes a chitosan based DDS in the form of microbeads that was formulated
and tested with both magnetic and electric stimuli. A MagneTherm (Nanotherics, UK) was used
to provide magnetic stimulation, whereas electric stimulus was initially applied by using a
Surface Acoustic Wave (SAW) resonator chip, and later with an inkjet printed interdigitated
electrodes (IDE). Stimuli were applied in multiple spans and in all instances, and drug release
was observed to be significantly higher when compared to the elution profile in non-stimulated
groups at the time of stimulation. This novel DDS will allow health-providers to choose one of
either modes or both in conjunction to administer drug dosages non-invasively and without
discomfort to the patient, allowing better regulation over dosage amount and timings and overall
therapeutic effectiveness.
1.2 RELATED WORKS
1.2(a) Drug Release by Magnetic Field Stimulus:
Gilchrist et al demonstrated magnetic hyperthermia in tissues with Ferric Oxide
nanoparticles in 1957 [6]. This breakthrough was followed by new therapeutic uses of
hyperthermia like cancer treatment and drug delivery.
Drug release by hyperthermia was first demonstrated in 1987 [11] when polymeric matrices
were designed with embedded magnets. They were loaded with insulin and implanted in diabetic
rats. After stimulation by a magnetic field, the glucose level dropped by 30% more than the
glucose drop observed in the rats that did not receive the stimulation. A similar insulin release
from alginate/chitosan microbeads was observed by Finotelli et al when they applied an external
magnetic field of 1800 G, 33 Hz [12]. Koppolu et al designed MNP cores with outer
multilayered shells of the temperature-responsive polymer poly(N-isopropylacrylamaide)
(PNIPAAm) and poly(D,L-lactideco-glycolide) (PLGA) as carriers of both curcumin and bovine
2

serum albumin (BSA); while curcumin showed a sustained release profile over 13 days, BSA
could be burst-released from PNIPAAm layer by elevating temperature [13]. Katagiri and his
group designed polyelectrolyte hollow multilayered shells containing dye, coated with Fe3O4
MNP and an amphiphilic bilayer. They magnetically irradiated at 236 Oersted, 360 kHz for 60
min and measured dye release, which was associated with a heat-induced change in phase of
amphiphile membrane, rather than any structural fissure [14].
Drug delivery by magnetic hyperthermia can be broadly classified into two mechanisms:
through bond breaking and through enhanced permeability [15]. The proposition in the first type
is that MNP forms bonds with the drug molecule which is damaged due to heat or vibrational
energy generated by MNP in a magnetic field. As an extension of this hypothesis, it is also
possible that the drug molecules form chemical bonds with the polymer or cross-linker which are
broken down due to heat generated by MNP. To demonstrate this mechanism, fluorescent DNA
was tethered to MNP and implanted in mice. After stimulation, fluorescence was detected in
surrounding tissues [16]. In the second proposed mechanism, intense localized heating by
magnetic hyperthermia causes fissures in the polymer matrix, thus releasing the drug. This
technique was used to deliver drugs in an on-off pattern, from a PNIPAm/cellulose based
polymer embedded with MNP, by thermally modulating the polymer permeability via a magnetic
field [17]. Hu et al formulated Fe3O4/poly(allylamine) polyelectrolyte microcapsules
encapsulating doxorubicin hydrochloride, which formed micro-cavities releasing high drug
quantities, under a magnetic stimulation [18].
1.2(b) Drug release by Electric Field Stimulus:
The applications of drug release by electric stimulation have not been as vastly researched on
as magnetic hyperthermia. In one of the earliest works, Miller et al showed that applying a low
3

voltage of 1 V to a polypyrrole films could induce higher glutamate release from the films
compared to glutamate release from non-stimulated films [19]. Some researchers implanted
polypyrrole nanoparticles loaded with fluorescent molecules in mice and detected release upon
applying 1.5 V/cm electric field for 40s [20]. Kwon et al. formulated a PMMA based polymer
system which had the capability to dissolve rapidly when an electric current was passed through
it. They used this property to cause insulin discharge from such hydrogel “patches” [21].
Fantozzi et al. covered electrodes with guar gum hydrogel carrying bleomycin solution. The
electrodes were then brought in contact with cancer cells and on applying an electric field,
bleomycin was directly delivered to them [22]. Polyaniline based hydrogel had similar electroresponsive properties that were proportionately dependent on the intensity of voltage applied
across the substrate [23]. Alginate films have also been used for electrochemically controlled
release of bovine serum albumin (BSA) or lysozyme [20]. Liu et al. developed a miniature drug
delivery device that was designed as an array of metallic contacts on a silicon base. They used
electro-responsive Polymethacrylic acid hydrogel as the Drug Delivery System (DDS) for
various drugs. This hydrogel reservoir could shrink or swell in response to the applied electric
field, thus releasing drugs [24]. There were no previous reports describing an electrically
stimulated drug delivery mechanism based on chitosan and magnetic nanoparticles.
1.3 RESEARCH OBJECTIVES, APPROACH AND SCOPE
The DDS tested in this study was a chitosan framework structured as microbeads and
containing magnetic nanoparticles (MNP). Over the course of this work, several cross-linkers
like PEGDMA and glyoxal were tested, and the microbeads loaded with different antibiotics like
tetracycline, vancomycin, etc. The current formulation is chitosan/MNP cross-linked with
PEGDMA and carry vancomycin as the drug molecule of interest. The objective was to trigger a
4

drug release controllably, repeatedly and non-invasively by an external stimulus, as
conceptualized in the sketch drawn in Fig. 1.1. In an ideal scenario, the drug would have been
restrained inside the DDS, until an external stimulus is applied to release it. In practical settings,
however, the DDS passively discharges drug and the stimulus is expected to elevate the drug
release at a later time-point when higher therapeutic levels of drug are desired. Magnetic and
electric fields have been explored as potential approaches to modify a traditional drug elution
profile and increase drug release in the stimulation duration.
A MagneTherm (Nanotherics, UK) was used to provide a high frequency magnetic stimulus
of 109.9 kHz at 25 mT. Various timelines were designed to provide stimulus as this research
progressed. The short-term accelerated studies typically span a few minutes (for electrical) or a
few hours (for magnetic). The long-term studies stretch over several days (for magnetic), with
stimuli given to the samples when the antibiotic elution drops below therapeutic levels.
Both magnetic and electric stimuli were explored to alter normal drug elution profile and
escalate its release from the chitosan microbeads. For each test, assuming μstim is the average
drug concentration eluted by stimulated groups and μctrl is the average drug concentration
released by control groups in each time period under consideration, the null hypothesis (H0 ) and
alternate hypothesis (H1 ) are defined as:
H0 : μstim = μctrl
H1 : μstim > μctrl
In descriptive terms, the null hypothesis H0 is that the stimuli do not have any effect on the
DDS and both groups have a similar drug elution profile. The alternative hypothesis H1 is the
stimuli is capable of influencing the DDS in such a way that the test groups release a
significantly higher amount of drug compared to control. The raw data was analyzed with t-tests
5

or Wilcox non-parametric tests coded in R programming language, assuming 5% significance
level. The results showed promise of developing a smart DDS that will allow control over dosage
discipline, duration and strength by external non-invasive excitation.
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Chapter 2
STEALTH ENGINEERING FOR IN VIVO DRUG DELIVERY SYSTEMS
2.1 INTRODUCTION
Since the later half of 20th century, there has been an escalating interest in developing an
ideal drug carrier that could be injected intravenously, endure a long circulation period and
release drug in a controllable manner. This could facilitate external monitoring and regulation
over drug dosage without causing the discomfort of repeated bolus injections to the patient. In
addition, target-specific drugs could be administered easily without degradation in vivo prior to
the intended delivery period. Numerous types of systems have been developed for this purpose;
however, most suffer from surface opsonisation by plasma proteins and are eliminated from
circulation.
2.1(a) Mononuclear Phagocytic System:
The mononuclear phagocytic system (MPS), traditionally referred to as reticulo-endothelial
system (RES), is a part of the immune system and consists of cells that originate in bone marrow
and ultimately settle in tissues as macrophages. The monocyte/macrophage cell family plays a
key role in the body’s innate and adaptive immune responses and is on the front line for
detection of foreign molecules and pathogens. Macrophages are a complex heterogeneous group
of cells found throughout the body and provide a vast number of functions. The monocytes
migrate from the blood into tissue to replenish long-lived tissue-specific macrophages of the
bone (osteoclasts), alveoli, central nervous system (microglial cells), connective tissue
(histiocytes), skin (Langerhans), gastrointestinal tract, liver (Kupffer cells), spleen and
peritoneum1. These cells are phagocytic and search for older worn out or damaged cells such as
erythrocytes (to conserve iron and hemoglobin) and virally infected cells to clear them from the
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circulatory system2. They also remove cellular debris from cells, such as neutrophils, that have
undergone apoptosis as well as foreign debris found in the body including that from implanted
biomaterials3. The macrophage’s phagocytic actions replenish this debris ceaselessly from the
tissue without producing inflammatory or immune mediators4. However, debris from cells that
have undergone necrosis give off molecular danger signals such as DNA and heat shock proteins
that activate the macrophages to secrete pro-inflammatory cytokines5. The role of classically
activated macrophages in host defense to intracellular pathogens has been well documented1,6-8.
Classically activated macrophages release growth factors like PDGF and vascular endothelial
growth factor (VEGF) to initiate repair, and produce inflammatory cytokines such as tumor
necrosis factor α (TNFα), macrophage inflammatory protein, IL1-α, IL−6, IL-8, and inducible
nitric oxide synthase (iNOS or NOS2) to activate cellular programs amplifying their own and
other immune cells’ antimicrobial activities and interleukin 1 (IL-1) and IL-6 to mobilize other
immune cells2.
The macrophages detect these danger signals through specific receptors such as the Toll-like
receptors (TLRs), intracellular pattern recognition receptors and the IL-1 receptor4,9-10. These
receptors have evolved over millions of years to detect pathogen associated molecular patterns
(PAMPs) related to pathogenic molecules such as lipopolysaccharide, lipoteichoic acid and
muramyl peptides derived from peptidylglycans. TLR activation then initiates signals (e.g.
interleukin receptor associated kinases (IRAK)1 and 4) activating the transcription factor NFκB
and regulating inflammatory gene expression11-12. These macrophages detect the bacteria in this
process and become primed and activated giving off microbicidal oxygen radicals such as
superoxide anions oxygen and nitrogen free radicals that kill pathogens as well as proinflammatory cytokines such as IL-6, IL-23, IL-1b and TNFα. Enhanced release of superoxide
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has also been shown to occur in response to IFNg, irradiation, pH, osmolarity and temperature
changes13-16.
The body has a number of different molecules such as complement proteins, fibronectin, and
vitronectin that may associate with biomaterials or introduced molecules17. The interactions of
these endogenous proteins with the biomaterial may change the nature of the biomaterial or the
endogenous protein such that local macrophages may become activated. Therefore, avoiding or
regulating macrophage priming and activation in a way that would inhibit the activity of other
immune cells is a goal of stealth molecule technology. One possible group of regulatory
molecules is the prostaglandins (PG). High concentrations of PGE2 are found at sites of infection
where it inhibits macrophage proinflammatory functions such as phagocytosis, reactive oxygen
species (ROS) production, release of antimicrobial peptides, and the production of TNFα, MIP1α and LKT B4 while enhancing the production of anti-inflammatory IL-1018-19. PGE2 also
inhibits ROS and leukotriene production by neutrophils, may enhance production of endogenous
IL-10, which down–regulates dendritic cell functions20-21. Finally, prostaglandins inhibit
fibroblast collagen and fibronectin synthesis and PDGF-stimulated migration22-23.
Stealth engineering is the generic term assigned to Drug Delivery System (DDS)
modification to delay its opsonisation and ultimately renal elimination. This review provides a
summary of recent research in stealth engineering for in vivo DDS that is of particularly high
interest for many therapeutic applications including chemotherapy for cancer, tumor treatment,
bone regeneration and blood sugar management.
2.1(b) Need for Stealth Engineering:
The foundation for DDS was probably laid by Bangham who reported selective restriction to
diffusion of cations by swollen bilayer ovolecithin structures24, also known as Bangasomes or
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liposomes. It was followed by abundant research on these structures25-32. Several other
researchers proposed other DDS structures, such as, dendrimers, polymer nanoparticles, micelles
and red blood cells.
From ingestion to final therapeutic activation, a drug carrier has to encounter several
deterrent factors. Segal et al. injected radio-labeled compounds entrapped by liposomes in rat
testicle and recorded testicular radioactivity, attributing the liberation to probable macrophagal
endocytosis27. Carrier characteristics like surface chemistry, charge, flexibility, size, and shape
have an acute influence on its in vivo lifetime. Designing an optimal carrier for maximal efficacy
is a vast research area in itself and has been explored extensively. It was suggested that
adsorption of plasma protein on the surface of a drug particle caused clearance from circulation
after observing protein binding behavior in vivo and in vitro; a higher capability to bind protein
was associated with faster clearance kinetics33-34. The protein was suggested to consist of high
amounts of opsonin which triggered the phagocytic uptake by the MPS. Particles of size greater
than 200 nm were observed to accumulate in spleen while those smaller than 10 nm are prone to
glomerular filtration35-37. Also, since the glomerular membrane contains anionic polysaccharides,
cationic particles are sieved faster than anionic ones37. Hydrophobicity is another aspect that can
prematurely terminate vasculature circulation and is usually solved by grafting hydrophilic
polymers onto the carrier surface36-40. Increased flexibility and branching of these steric shields
further decreases macrophagal recognition by creating a high-density conformational barrier.
Nanoparticle shapes are also observed to affect pharmacokinetic behavior. Discher showed that
filamentous micelles had longer circulation than chemically similar spherical polyethyleneglycolated (PEG) vesicles41. Champion and Mitragotri fabricated worm-like polystyrene particles
with high aspect ratios (>20) and reported negligible phagocytosis compared to spherical
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particles of the same volume (1-3μm diameter), when tested against a rat alveolar macrophage
cell line42. They attributed this observation to reduction in curvature and limiting it to only the
endpoints of the worm shapes, which theoretically in turn should decrease phagocytosis.
Early attempts to curb phagocytic reaction to drug carriers by temporarily causing MPS
Blockade was by administering a pre-dose of similar particles. The effect of an intravenous high
dose of empty multilamellar liposomes on opsonisation rate of a second dose encapsulating 14Cinulin injected at 1, 5 and 24 h was studied in 198043. It was observed that compared to a control
group where only the second dose was given, 14C-inulin level in blood increased by a factor of
29 and decreased by a factor of 6 in liver when a preemptive dose was administered 1hr prior to
actual dose. A similar method describes injecting a pre-dose of large unilamellar liposomes to
limit the clearance of the second drug dose44. Further, different sizes of liposomes were
comparatively studied to understand the dependency, if any, of MPS flushing on particulate size
of such consecutive doses45-46. Small liposomes (40-200 nm) were shown to have a relatively
higher circulation as compared to their larger counterparts.
Dextran sulphate (DS) was also used to lower the rate of clearing foreign particles from the
blood stream by impeding MPS functioning, in some cases even resulting in absolute cessation
of immunological response47-48. Patel et al. demonstrated a suppression of liver uptake of
multilamellar liposomes from the blood stream by injecting a maximal dose of 50 mg DS per kg
of body weight that caused a temporary liver blockage lasting 48 hours49. Liver uptake was
observed to have dropped as early as 2 hours after infusion of DS. Prior dosage of a monoclonal
antibody such as 2.4G2 demonstrated an inhibition in clearance of liposomes loaded with
Dinitrophenyl50.
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The half-life and area under the plasma-concentration time curve are an accurate assessment
of how long the DDS survives in vivo. Toutain and Bousquet-Melou have defined plasma
terminal half-life as “following intravenous (IV) administration, the terminal half-life is the time
required for plasma/blood concentration to decrease by 50% after pseudo-equilibrium has been
reached; then, terminal half-life is computed when the decrease in drug plasma concentration is
due only to drug elimination, and the term elimination half-life is applicable”51. Zhang et al. have
published a detailed review in 2013 of materials that have been tested for drug delivery along
with the FDA approval dates for the successful ones52.
In this paper, we have reviewed some DDS that have been widely studied . Table I
summarizes important data of various formulations reported. The data provided are not intended
to highlight a negative comparison between their adequacies; they just serve the purpose of
providing knowledge about various developmental approaches to DDS. These data have been
primarily collected and summarized from the databases maintained through FDA archives and
Drugbank of Canada. Fig. 2.1 shows a layout of this review.

Fig. 2.1: Broad Classification of the types of DDS. Only major groups are shown here and
discussed in this paper
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2.2 ARTIFICIAL STEALTH ENGINEERING TECHNIQUES FOR IN VIVO DRUG
DELIVERY
Various types of polymers and other biological entities have been artificially developed for
the required camouflage ability of stealth engineered DDS for in vivo applications. Some of these
techniques have shown promise and been tested through animal studies. Major stealth
engineering techniques for in vivo DDS are discussed in this section.
2.2(a) Liposomes:
Liposomes are phospholipid bilayers that encapsulate drug in the inner compartment while
the outer bilayer acts as its shield (Fig. 2.2). Some drugs can also be entrapped in the vesicular
space. They were discovered by Bangham in 1961 and were extensively adopted as DDS,
followed by various approaches to extend their short half-life in vivo. A comparative study of in
vivo circulation time between non-entrapped neuraminidase and neuraminidase enclosed in
liposomes with varying lipid concentration was done by Gregoriadis et al.31. They reported a
higher circulation time for liposomes with a higher constituent of lipids, thus concluding that the
rate of renal elimination is dictated by the drug carrier, rather than by the drug itself. Further, it
was observed that cholesterol rich liposomes displayed enhanced in vivo lifetimes over
cholesterol-poor or cholesterol-nil liposomes by impeding serum opsonin binding53-55. Semple et
al. also noted that cholesterol inclusion improves packing density of liposomal phospholipid
molecules thereby decreasing ion permeability55.
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Fig. 2.2: Schematic of a copolymer liposome structure. The constituent building blocks have a
hydrophobic tail and hydrophilic head which self-assemble to form the unique bilayer
membrane. The liposomal surface can be conjugated to any functional molecule pertaining to the
desired application. It can also be PEGylated for increased steric shielding
Negatively charged liposomes cleared faster compared to neutral or positively charged
liposomes hence the negative charge on liposomes was labeled as a probable factor of
recognition by MPS34. As a remedy for this, liposomes were structured with a low molar fraction
of a negatively charged glycolipid, such as, GM134 or phosphatidylinositol, and a neutral
phospholipid used as the major constituent57. These modified liposomes that were termed as
sterically stabilized had a longer circulation time without MPS blockage. The effect of different
concentrations of ganglioside and sphingomyelin (SM) modifications in liposomes on liver
uptake was studied34,58-59 where it was conclusively demonstrated that these modifications
provided a longer life-time in vivo over classical liposomes. They were named as “Stealth
Liposomes”. The liposomes constituted of SM:PC:cholesterol:GM1 in the molar ratio 1 : 1 : 1 :
0.2 were classified as the first generation.
Abuchowski et al.60 were among the first to covalently couple PEG to a bovine liver catalase
which provided a hydrophilic shield around the enzyme and delayed recognition by the MPS.
This method transcended to liposomal modification by PEG and performed better than earlier
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methods that employed glycolipids. This was followed by several publications on superior
performance of PEGylated liposomes in vivo tested with various drugs61-75. Allen and Hansen
demonstrated an elaborate pharmacokinetic performance which was dependent on the dosage
effect between the stealth and conventional liposomes; a comparison was also made between the
half-lives of first generation GM1 liposomes and second generation PEG(1900)distearoylphosphatidylethanoalamine64,67,76. Gabizon et al. were the first to demonstrate the
extended blood lifetime of PEGylated liposomes encapsulating doxorubicin in human subjects68.
It was followed by clinical trials of doxorubicin in Stealth Liposomes on 15 HIV infected
patients for the treatment of Kaposi’s sarcoma69. Liposomes modified with PEG were also
employed as drug carrier devices for gene delivery, specifically for delivery of pDNA77 and
siRNA78. FDA approved Adagen, a polymer-drug conjugate of adenosine deaminase with PEG
in 1990 was followed by approval for PEGylated liposomal doxorubicin for cancer treatment in
1995. Many researchers investigated the versatility of PEGylated liposomes for various drug
deliveries, including those for cancer and conclusively established the higher lifetime of
PEGylated DDS78-94. Compared to the first generation stealth liposomes such as
monoganglioside (GM) and sphingomyelin (SM) liposomes mentioned above, PEGylated
liposomes demonstrated the ability to evade activating the immune system. However, gradually
several disadvantages were identified and associated with PEGylation in subsequent research,
known as the “PEG Dilemma”95. Earlier the pharmacokinetics of PEG-liposomes were proven to
be independent of dosage unless the quantity administered was too low, at which accelerated
blood clearance, abbreviated as ABC-effect was observed. This phenomenon occurred in
successive bolus injections of liposomes after a prior sample was already injected96-105. This
event is attributed to production of anti-PEG immunoglobulin (IgM) from spleen in reaction to
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the prior doses which increases uptake by Kupffer cells and can be suppressed to some extent by
choosing antiproliferative drugs or moieties37.
2.2(b) Polymeric Micelles (PM), Polymeric Nanoparticle, Solid Lipid Nanoparticles (SLN):
Micelles (Fig. 2.3) differ from liposomes in their structure. Liposomes are lipid bilayers (Fig.
2.2) that separate an internal aqueous phase from an external aqueous environment while PM are
lipid monolayers (Fig. 2.3) with two functional parts, an inner hydrophobic core that determines
loading efficiency of desired drugs and an outer hydrophilic shell that controls pharmacokinetic
behavior of the micelle in vivo39,106-7. The outer polymeric corona acts as a steric shield,
camouflaging the drug loaded in the solid inner core and can be conjugated to targeting or
recognition moieties. They are smaller in size (<100 nm) and have superior stealth properties
compared to liposomes. They are created by self-assembly of amphiphilic di-block or tri-block
copolymeric molecules, which are in turn a mix of hydrophilic and hydrophobic components.
Lee et al. showed the superior pharmacokinetic properties of polymeric vesicles over stealth
liposomes108. This class of DDS has gathered much interest because of their similarity to natural
biological transport systems; their unique characteristics delays uptake by RES while facilitating
efficient intracellular drug delivery109.
Any amphiphilic biocompatible polymer capable of significant steric hindrance such as PEG,
PVP can be used to make micelles39. A popular class of micelles, marketed as Pluronics®, also
known under the non-proprietary name of Poloxamers consist of polyethylene oxide (PEO) and
PPO in an A-B-A tri-block structure and have relatively long elimination half-lives compared to
liposomes99. For instance, P85 was shown to have a half-life between 60-90 h110.
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Fig. 2.3: Schematic of a Polymeric Micelle/ SLN. The inner matrix holds the drug cargo,
protected by the outer shell that maybe activated by attachment of various molecules.
Poloxamine (PX) and poloxamer were noticed to impart stealth properties when coated on
the drug particle. Illum and Davis were among the first to use them for modification of
polystyrene and PMMA nanoparticle111-112. Uptake by liver was seen to decrease by 20% and
40% for nanoparticle (NP) coated with poloxamer-188 and poloxamer-338, respectively.
Poloxamer-407 was seen to perform even better than either in terms of evading phagocytosis
while PX proved to be superior over poloxamer113. Rudt and Muller conducted an assay of NP
and microparticles pharmacokinetics affecting phagocytosis for polysterene modified by PX114.
Furthermore, Moghimi et al. established that injecting PX-908 caused rapid clearance of a
second dosage, most likely by resident macrophages and Kupffer cells from the previous dose.
Such a behavior was noticed to be exactly similar to coating the particle with PX-908115-116. The
modification with other polymers, such as, PLGA also exhibited enhanced circulation
lifetimes117-119.
PEG has also been widely used as a constituent of di-block and multi-block copolymer
micelles and shown to have longer circulation life-times109. Several stimuli-responsive PM have
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been designed120 and some are in final stages of clinical trials39. Tri-block copolymer micelles of
ABA and BAB combination of PEG and PLA were designed and tested as a DDS for paclitaxel
in mice121. Moffatt et al. used one such copolymer, PLGA-PEG-PLGA as a gene delivery
vehicle for encapsulated salicycl hydroxamic acid-PEI/pDNA122. Various other polymeric NP
were formulated and tested for suitability as a drug carrier. Verrechia et al. modified the
PLA/albumin to PLA-PEG copolymer and recorded an extended half-life of 6 hrs. over the
former’s few minutes123. Zhiqing et al. studied PEGylated PLGA NP (Stealth NP) as carriers for
arsenic trioxide and showed it had lower uptake by murine peritoneal macrophages compared to
naked arsenic trioxide124. Bazile et al. developed Methoxy based NP Me-PEG-PLA and recorded
a longer half-life of 6 hours compared to a few minutes for F68 coated NP125. It was followed by
other PLA-PEG complexed with NP for stealth delivery126-127. In addition, PEGylated PGLA
microparticles encapsulating VEGF with improved circulation times was proposed recently128.
Gref et al. structured nanoparticles with PLA and MPOE129 followed by Perachhia et al.
developing coated polycyanoacrylate NP and poly(isobutyl-2-cyanoacrylate) with PEG and
observed an increased circulation time and decreased cytotoxicity130-132. Ahmed and Discher133
designed PEG-PLA, PEG-polycaprolactone (PCL) and PEG-polybutadiene hydrolysis triggered
polymerosomes. PEG was incorporated to improve in vivo circulation and a comparison between
PEG-polymerosome and Stealth Liposome was presented. Lee et al. reported best half-life of
47.3±1.8 hours108 for polymerosome-10 while Photos et al. reported a half-life of 28±10 h for
OB16134, both a significant improvement over stealth liposomes.
PEO was extensively studied as a prospective drug particle shield. Jaeghere et al. modified
NP with PEO and the factors that determined MPS uptake were assayed135. Vittaz et al.
conducted a similar study with a complex of PLA-PEO, and concluded that the decrease in
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phagocytosis is directly proportional to surface density of PEO136. PLA nanoparticles when
modified into a di-block copolymer by MPEO) were seen to undergo delayed phagocytosis in
guinea pigs137. Butsele et al. tested (P2VP) (PEO) (PCL) tri-block copolymer as a pH-triggered
drug delivery device and found it to possess stealth behavior138. A detailed review of various
polymeric coatings and the behavior of complement activation mediated by polymeric structure
is provided by Salmaso and Caliceti 139.
NK911, a micelle with a diameter of 40 nm constructed from PEG-poly(aspartic acid) block
copolymer, encapsulating doxorubicin was the first polymeric micelle that was approved for
clinical trial on 23 patients with malignant tumor140. While PEG formed the outer core, adding
the “stealth” characteristic, the poly(aspartic acid) chain conjugated to doxorubicin built the
inner hydrophobic core. The dosage was gradually increased from 6.0 to 67 mg doxorubicin
equivalent m-2 in several levels. The half-life for NK911 was observed to be longer for NK911
compared to free drug. Following this, several other micelle structures were developed that
proceeded to human trials141. Micelles have been conjugated to antibodies, nucleic acids,
peptides and other biomolecules to augment target specificity and localization.
SLN are usually characterized by a solid lipid core proposed as an alternate drug carrier142.
Following this Bocca et al.143 modified SLN with two types of
dipalmitoylphosphatidylethanolamine-PEG and stearic acid PEG as a stealth agent for
fluorescent rhodamine B. Stealth SLN were noticed to be non-phagocytized after 60 min of
administration compared to phagocytosis of plain SLN in few minutes. This was followed by the
use of Stealth SLN to deliver doxorubicin in rats144 and Icariin in mice146. Madan et al. also
employed PEG nanoparticles to deliver noscapine across the blood-brain barrier (BBB) to
glioblastoma cells147.
23

2.2(c) Dendrimers:
Dendrimers (Fig. 2.4), a whole new class of drug carriers, were proposed in 1980s148. Since
then, these highly branched macromolecules with low polydispersity have been extensively
explored as drug carriers. They garnered much interest as a pharmaceutical vehicle because of
their unique structural properties. They have a central core that can be loaded with hydrophobic
drugs, a branched shell that can impart steric stability, and surface 3D moieties that can be
conjugated with targeting bioactive molecules149. Polyamidoamine (PAMAM) dendrimers or
STARBURST® dendrimers are the most common; dendrimers made of poly(lysine),
poly(propyleneimine), polyester, polyol and triazine. PEGylated dendrimers with a
comparatively longer terminal life-times have been reported too150-152. It was observed that
cationic dendrimers were flushed out of circulation in Wistar rats at much accelerated rates
compared anionic dendrimers, which re-confirmed that surface charge is a factor that
significantly determines opsonisation rate151. Detailed pharmacokinetic dependency between
dendrimer shape and drug content on its longevity in vivo has been studied153-154.
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Fig. 2.4: Schematic of PAMAM dendrimer. Starting from an initiator core, the branching
increases outwards in a tree like structure which is terminated by amine branches. The dendrimer
surface can also be conjugated to other molecules by correct protonization
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Vivagel™ from Starpharma, an amide based (SPL7013) dendrimer microbicide was cleared
for clinical trials against herpes simplex viruses (HSV) and human immunodeficiency virus
(HIV) in 2004155-157. SPL7013 has a core of benzhydrylamine amide of L-lysine bonded to four
layers of L-lysine branches; each of the 32 amine groups on the surface were terminated by a
sodium 1-(carboxymethoxy) naphthalene-3,6-disulfonate group It has been suggested that
SPL7013 attached itself to gp120 proteins on viral surfaces, thus preventing it from adhering to
human cells.
2.2(d) Polymeric Modifications of other Substrates:
Liu et al. grafted PEG onto single walled nanotubes (SWNT) and noticed an increase in
circulation time with increase in chain length158, recording 15 h for triple branched PEG grafted
onto SWNT. Prencipe et al. reported 22.1 hr for PGA-pyrene-mPEG159. Niidome et al. layered
gold nanorods with PEG to decrease its cytotoxicity and increase its lifetime with an objective of
photo-thermal therapy and/or photo-controlled DDS160-161. Yokoyama et al. conjugated the antitumour drug, Adriamycin (ADR) with PEG and showed it to have a longer half-life of 70 mins
over 18 min for non-complexed ADR162. Zhou et al. used camptothecin (CPT) to form PEGblock-dendritic polylysine-CPT nanospheres/nanorods of different sizes intended for drug
delivery to cancerous cells163. PEG-tetra-CPT-nanorods with dimensions < 500 nm were found
to have longest life-time and target specificity among all other sized nanorods.
In 1997, Cho et al. proposed a carbohydrate coating of NP that eluded phagocytic tagging by
MPS164. Same year Maruyama et al. developed a new class of gene carrier with polysachharide
and PLA grafted onto poly(L-lysine)165. Recently, super paramagnetic iron oxide (SPIO)
nanoparticles are gaining popularity as MRI contrast agents and for treatment of cancer by
hyperthermia. SPIO are not biocompatible and need to be shielded from phagocytosis. SPIO with
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surface-modification with chitosan166, PLA-PEG167, PEG168 and PEG-poly(amino) acid169 have
been proposed.
2.3. NATURAL AND SEMI-NATURAL STEALTH ENGINEERING TECHNIQUES FOR
IN VIVO DRUG DELIVERY
Liposomes, PM, SLN and dendrimers are artificial DDS developed in an attempt to extend
drug longevity in vivo. However they were still subjected to rapid elimination from the blood.
This motivated several researchers to explore natural biological structures as potential DDS like
erythrocytes, and capsids. The following section is a short review on such developments.
2.3(a) Red Blood Cells (RBC/Erythrocytes) based:
RBC are anucleate cells that transport oxygen and carbon-dioxide between lungs and body
tissues via the circulatory system. In humans, healthy mature RBCs are bi-concave shaped,
around 7.7 μm in diameter and have a lifetime of approximately 120 days. Their cytoplasm
contain haemoglobin, a metalloprotein of iron which binds with oxygen. RBCs are found in all
vertebrates (except the family Channichthyidae) and a few invertebrates. The discocytes are
biocompatible, abundant, non-toxic and normally do not instigate MPS for opsonisation.
Additionally their anucleate nature allows a considerably inert intracellular condition and high
loadability of drugs. These aspects make it a probable DDS with extended vascular circulation,
thereby reducing the frequency and intensity of dosage170-171. A common method to insert a load
in RBC is lysis of RBC in hypotonic solutions, followed by drug absorption and membrane
resealing. However this method almost always caused haemolysis, irreversible morphological
damage to RBC structure and phosphatidyl sterine (PS) exposure. PS has been associated with
early removal of RBC by MPS172. RBC can also be loaded by pre-treating with chlorpromazine,
which causes reversible swelling and endocytosis of payload. In other research, RBC membranes
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were fused with liposomes containing the therapeutic load, the liposomes then release it
gradually inside the erythrocytic cell172-173. Other common methods are electroporation by
exposure to a strong electric field and drug induced endocytosis170. In 2014, Yang et al. proposed
a novel method of loading protein into RBC by using covalent bonding between the protein and a
cell-penetrating peptide (CPP) via a disulfide link174. The CPP penetrates the RBC without any
membrane disruption. Once inside the RBC, the disulfide bond dissociates, thus successfully
enclosing the protein inside the cell and ensuring its structural and functional integrity.
RBCs have surface antigens that react with antibodies present in the blood of a different type.
This necessitates proper matching during transfusion. To facilitate easy transfusion without
cross-matching, shielding the antigens by modifying RBC with mPEG was first achieved by a
group of Korean researchers in 1996175. This was soon followed by other researchers, some
attempting to optimize polymer structure with respect to cytotoxicity176-183. Scott and Chen
extended PEGylation to other allogenic and xenogenic cells including white blood cells184.
Several drugs have also been successfully encapsulated and tested in vivo170-171. One of the
early clinical studies on 9 volunteers using 51Cr labeled autologous RBC had a normal in vivo
half-life of 19-29 days185. It was succeeded by another clinical study of PEG-conjugated
adenosine deaminase (pegademase) and native adenosine deaminase (ADA) loaded 51Cr labeled
RBC by hypo-osmotic dialysis. They reported a half-life of 20 d and 12.5 d for erythrocyteentrapped pegademase and ADA respectively, compared to 3-6 d of exposed pegademase186.
Mitragotri and Chambers attempted non-covalently binding of polystyrene nanoparticles of 200450 nm size to RBC membrane and injected in Sprague-Dawley rats. They observed an
increment in circulation time for the RBC-nanoparticles; around 5 % of them were still
circulating after 12 h whereas >99.9 % of unbound particles were cleared in 2 min187. In a
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clinical trial to evaluate potency of low doses of corticosteroid in cystic fibrosis patients,
autologous erythrocytes were loaded with dexamethasone 21-phosphate and administered to 17
patients in two phases over a time interval. While no side-effects or toxicity were recorded, a
persistent level of dexamethasone was detected in plasma at least up to 10 days after injection,
proving efficacy of these low dexamethasone doses over standard direct therapeutic dosage188.
Amikacin, an aminoglycoside antibiotic, was encapsulated in RBC for protection against
enzymatic degradation and targeted to peritoneal macrophages in rats. The study revealed a
significant improvement in pharmacokinetics of the antibiotic with more than five-fold increase
in half-life of enclosed drug over the free drug189,190. Phenylalanine hydroxylase (PAH) is an
enzyme that initiates and controls processing of phenylalanine, an essential amino acid.
Deficiency of PAH can cause phenylketonuria. To find a sustained alternate enzyme replacement
therapy for PAH, Yew et al. enclosed PAH in RBC by hypotonic dialysis and injected in mice.
They observed a persistent level of PAH in circulation for at least 10days and a decrease of
phenylalanine levels by 80%191. Chitosan is another popular colloidal drug delivery substrate,
however as an intravascular DDS, they are flushed out from circulation easily. To extend its
lifetime, low molecular weight chitosan was attached onto RBC surface by electrostatic
attraction and the combination was demonstrated as a feasible DDS192. Among several such
therapeutic molecules enclosed in RBC, some are immunophilin193, paclitaxel194, bovine serum
albumin195, piperine196 and interferon-alpha 2b197. Apart from drugs, they have also been used to
encapsulate gold nanoparticles to facilitate high contrast in dynamic X-ray imaging198 which
indicate the flexibility and lucrativeness of RBC as a functional DDS.
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2.3(b) Viral Capsids based:
Viruses are submicroscopic parasitic agents that are characterized by an RNA/DNA core
encapsulated by a protein coat. They can effortlessly penetrate living cells and cause unwanted
effects, such as, infection or mutation. However, because of this same property, platforms
derived from viral sources have been evaluated as a likely DDS199. Capsid is the outer shell of a
virus composed of protein sub-units called capsomeres. The viral genetic material is extracted
and substituted by the desired load and the capsid is re-assembled again199. Such a process
prevents them from replicating and infecting the host, while still retaining their MPS evasive
properties. Viral vectors are slowly gaining preference as a carrier of transgenes for gene therapy
because they enable efficient transfer and sustained gene expression. Cooper and Shaul utilized
hepatitis B viral capsid to enclose Oligonucleotides (ON). They first permeabilized the virus and
treated it with ribonuclease, causing evacuation of endogenous RNA. This process was followed
by incubation with ON and capsid restructuring which successfully encapsidated ON200. They
also tested these particles on cultured HeLa cells and observed a higher cell uptake than naked
ON and no cytotoxicity, providing proof of it being a viable DDS. Adeno-associated viral (AAV)
serotypes were obtained by transfection of 293T cells201. AAV was then injected into neonatal
mice brain at delivery and sacrificed after 30 days. An examination of the brain sections has
affirmed efficient transduction. AAV have also been used to provide a media for conjugation and
delivery of paclitaxel202. This could eliminate the potential virulence of chemical solvents
currently used to deliver paclitaxel, which has a low water solubility. Several viral vectors were
modified for gene transportation in lacrimal glands and have been thoroughly reviewed by
Trousdale et al.203. Plant viruses are expected to be less pathogenic and immunostimulatory than
animal virus and several of them have been used to show viability as a DDS. A group of
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investigators encapsulated doxorubicin in hibiscus chlorotic ringspot virus and targeted it to
ovarian cancer cell line, observing a statistically higher uptake and cytotoxicity in cancer cells204.
Cucumber mosaic virus was also loaded with doxorubicin and conjugated with folic acid as a
targeting moiety205. It was tested both in vitro and in vivo and exhibited enhanced antitumour
action and lesser cardiotoxicity.
2.3(c) Deoxyribonucleic Acid (DNA) Based Drug Delivery Systems:
The quest to develop an ideal DDS that avoids opsonisation and renal flushing by MPS
recognition as a native molecule has seen the design of a novel group of delivery structures based
on the endogenous structure of DNA. DNA is a biopolymer that encodes genetic information
uniquely characterized to every living organism. It is inherently biocompatible, biodegradable,
physiologically stable and has engaged much interest over the past few years as an efficient
DDS206. DNA consists of two polynucleotide strands coiled helically. Each nucleotide in a strand
is constructed from either one from purine bases (adenine, guanine) or one of pyrimidine bases
(cytosine, thymine) on a deoxyribose sugar and phosphate backbone. The phosphate of one
nucleotide covalently binds to the sugar of adjoining nucleotide while its nitrogenous base forms
a pair with the base of the other strand, together also known as base pairs. Base pairs can only be
formed between adenine and guanine or cytosine and thymine and this is commonly termed as
complementary base pairing.
The famous DNA origami technique proposed by Paul Rothemund207 is contingent upon the
unique base pairing feature of DNA (Fig. 2.5(a)). He manipulated DNA strands by short
complementary synthetic oligonucleotide staples into various shapes and patterns such as smiley
face, map of China/North America and stars. Joyce and group were the first to use DNA origami
to create three dimensional structures and were followed by other research groups208. Ko et al.
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utilized 52-base long, single-stranded DNA with four palindrome segments to self-assemble into
DNA-nanotubes of length 50-200 nm and diameter 40 μm to delivered Cy3 to cancer cells209.
Krishnan et al. described the potential of these nano-structures for cargo delivery by designing
DNA icosahedra using a modular assembly approach and encapsulated it with gold nanoparticles
(Fig. 2.4)210. These structures are suitable for drug delivery because of their high capacity to
carry drug, well defined structure, biocompatibility, stability in physiological environment and
commendable half-lives211. 2D triangular and 3D tubular origami structures were independently
loaded with doxorubicin by intercalation and exposed to regular and doxorubicin resistant human
adenocarcinoma breast cells (MC7)212. It was observed that while the DNA nanostructures, by
themselves were not cytotoxic to the cell line, the ones loaded with drug induced cell-death in
both types of MC7, whereas free doxorubicin was ineffective against the resistant type. Another
group conjugated DNA tetrahedron with doxorubicin and it to both receptive and resitive MC7
cell lines. They obtained similar results which confirmed that DNA nanostructures had an
enhanced intracellular uptake and were thus capable of reversing their drug resistivity213. Huang
et al. incorporated doxorubicin in DNA-icosahedra (Doxo@DNA-icosa) and aptamer conjugated
DNA-icosahedra (Doxo@Apt-DNA-icosa) and exposed it to MUC-1 negative Chinese hamster
ovary cell (CHO-K1) and MUC1-positive human breast cancer cell (MCF-7) cultures214.
Doxo@Apt-DNA-icosa showed a higher intracellular absorption in MCF-7 but not CHO-K1
cells, compared to Doxo@DNA-icosa and a higher cell lethality to MCF-7 compared with freedoxorubicin and Doxo@DNA-icosa. These data indicate the possibility of an efficient targeted
DDS. Ahn et al. formulated a cancer cell-targeting DNA hybrid duplex of DNA-cholesterol and
DNA-peptide which self-assembled into liposomal NP in solution and was then loaded with
doxorubicin215. These NP released drug at acidic pH, thus demonstrating their capability of
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functioning as a controllable smart drug. Another research group loaded similar DNA complex
with circumin and docetaxel at a high loading efficiency and studied its cytotoxicity against
human lung cancer cell line A549216.
Chitosan, another biocompatible polymer sourced from chitin was paired with DNA and
doxorubicin as a nanocomplex and was seen to have an extended half-life compared to naked
DOX. Its efficacy was also verified against various cell lines217. Rolling circle amplification
(RCA) is an isothermal process that generates very long periodically sequenced single stranded
DNA. DNA nanoribbons were fabricated by RCA and a few staple oligonucleotides218. They
were the coupled with CpG oligodeoxynucleotides as a model drug to prove functionality as a
viable DDS. DNA hydrogels composed of CpG DNA were used to deliver doxorubicin and CpG
motifs219. Andersen et al. proposed an advanced delivery system in which they designed a
“DNA-box” of dimensions 42 × 36 × 36 nm3 that could only be opened by a matching
oligonucleotide “key”220 (Fig. 2.5(b)).
(a)
Adenine
Thymine
Guanine
Cytosine

(b)

DNA building blocks

Therapeutic Payload

OLIGONUCLEOTIDE
“KEY”

Specific nucleic sequence that
responds to a specific key

Fig. 2.5: (a) Structure of a DNA showing Watson-Crick complementary pairing. Adenine can
bond only with Thymine and Guanine with Cytosine. (b) DNA box that can ideally be used to
store drug molecules until the lid is opened by an oligonucleotide chain complementary to the
“lock”
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TABLE 2.I: Summary of DDS products developed for in-vivo applications in recent years that utilize stealth engineering technique

Type

Polymeric
Micelle

Drug Load

C onstitue nts
of
modification

Siz e

Genexol

Paclitaxel

mPEG-PDLLA

<50 nm

NK105

Paclitaxel

PEG-P(Asp)

85 nm

Name of
Product

Elimination Elimination
Half-life (of
Half-life
drug) be fore
afte r
modification modification
0.98-1.84 h
(dose
dependent)
0.98-1.84 h
(dose
dependent)

11.0-17.9 h
(dose
dependent)
5.99 h - 6.82h
(dose
dependent)

Plasma
AUC
(be fore )

Plasma
AUC
(afte r)

Inje cte d
Dose

Te st
Subje cts

Re f No.

n.a

27490±8.29
7 ng h/ml

390
mg/mm 2

Humans

145, 146,
147

309.0 μg
h/ml

15573.6 μg
26-Bearing
100 mg /kg
h/ml
CDF1 mice

145, 147

75.73
±26.13 μg
h/ml

1335.47 ±
75.99 μg
h/ml

5 mg/kg

BALB/c
nude Rats
implanted
with MKN45 cancer
cell line

145,148,
drugbank

1620.3
±1062.9 ng
h/ml
1620.3
±1062.9 ng
h/ml

4174.1 ±
471.2 ng
h/ml
2190 ng
h/ml
(approx)
1045 μg
h/ml

50 mg/mm 2

Humans

145, 149

50 mg/mm 2

Humans

145, 149,
150

1% wt

C57/Bl/6
mice

145, 144

NC-6004

Cisplatin

PEG-P(Glu)

30 nm

20-30 min

6.43h

NK911

Doxorubicin

PEG-P(Asp)

40 nm

5-10 min

1.6-4.7 h

SP1049C

Doxorubicin

Pluronic
F127,L61

30 nm

5-10 min

48.8 h

A-B-A type of
PPO and PEO

n.a.

5-10 min

90 h (for 1 %
wt dose)

n.a.

Pluronic 85 Doxorubicin

Ps10

FIT CDextran

PEG-PDLLA ::
10:90

96.3±6.6
nm

< 2h

47 ±12.7 h

n.a

2634±258
%ID h/ml

100 mg/kg

C57Bl/6J
female mice

101

-

Adriamycin

PEG-P(Asp)

50 nm

18 min ( at 10
mg/kg)

70 min

n.a

n.a

0.1 ml/10 g

C57BL/6
male mice

179
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TABLE 2.I (continued)

Type

Name of
Product

tHA-LIP

Stealth
Liposome ®

Drug Load

Siz e

Doxorubicin

Hyaluronan

81 nm

5-10 min

400 nm

16-20 min

1-β-DHSPC:CH:PEGArabinofuran
DSPE :: 2:1:0.1
osyIcytosine

Conventional
Liposomes
Stealth
Liposome ®
Stealth
Liposome ®
Liposome

Conventional
Liposomes
DSPC
Liposomes

Stealth
Liposome ®

Stealth
Liposome ®
Conventional
Liposomes
Stealth
Liposome ®

Elimination Elimination
Half-life (of
Half-life
drug) be fore
afte r
modification modification

C onstitue nts
of
modification

PC:CH::2:1
SM: PC:CH
:GM1::1:1:1:10
%
SM:PC:CH:PEGDSPE ::
1:1:1:10%
SPC :
cholesterol ::
4:1
DSPC :
cholesterol ::
Flurbiprofen
4:1
DSPC :
cholesterol :
DSPE-PEG ::
4:1:0.2
DSPC/Chol/DPP
Mitoxantrone
E-PEG2000 ::
50:45:5

PC:chol:PEGPE::1:1:0.16

Plasma
AUC
(afte r)

Inje cte d
Dose

Te st
Subje cts

Re f No.

139 h

-

tHALIP/free
DXR = 47

10 mg/kg

Mice

192

12h

n.a

n.a

0.5 μmol

Leukemia
Bearing Mice

59

10 μmol

Female Mice

56

43924.1 ±
24.440
ng/ml/h
512669 ±
151650.7 ±
21.640
16.760
ng/ml/h
ng/ml/h
704408.3 ±
77.430
ng/ml/h

2.5 mg/kg

Male Albone
Wistar
Arthritic Rats

193

n.a

*10.95 μ
mol h ml-1

10 mg kg-1

female BDF1
mice

68

n.a.

n.a

0.12-0.14
mg

male Balb/c
mice

54

89295 nmol
h/ml

13 h
92-123
nm

21.6 h

-

-

168 nm

182 nm

7.36 h

7.84

2.31 h

192 nm

19.87 h

n.a

<30 min

0.2μm

-

n.a

138754
nmol h/ml
170150
nmol h/ml

24.8 h

PC:Chol :: 1:1
-

Plasma
AUC
(be fore )

<30min
5h
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TABLE 2.I (continued)

Type

Name of
Product

Drug Load

C onstitue nts
of
modification

Stealth
Liposome ®

Liposome

Doxorubicin

Stealth
Liposome ®

FIT CDextran

Conventional
Liposomes

DSPC:chol:DSP
E–PEG–COOH
::6:3:0.6

70 ± 19
nm

DPPC:chol:PEGDSPE::1.85:1:0. 103 nm
15)
PLA:Albumin

IBP 5823

Stealth SLN
(SSLN)

5.476 ± 1.690
h

< 2h

22.238 ±
2.059

10.6±1.8 h

Stearic Acid,
Epikuron 200
Stearic Acid,
Epikuron 200,
PEG

Plasma
AUC
(be fore )

0.538 ±
0.145 μg
h/ml

n.a.

2-3 min
n.a.

PLA:PEG

Doxorubicin

Elimination
Half-life
afte r
modification
20.584 ±
0.905

160 nm

Plasma
AUC
(afte r)

Inje cte d
Dose

Te st
Subje cts

Re f No.

5 mg/kg

male ICR
mice

67

797±46
(%ID h/ml)

70 mg/kg

C57Bl/6J
female mice

101

10 h μg/ml

8 mg/kg
SpragueDawley rats

116

1276.458 ±
195.444 μg
h/ml
1221.262 ±
80.795 μg
h/ml

n.a.

120 nm

Stealth
DPPC:chol:DSP
114 ±
Liposome ®
E-PEG
32nm
Monensin
Stealth
DPPC:chol:DSP
127 ± 41
ImmunoLipo
E-PEG + antinm
some ®
MY9 antibody
Stealth
PHEPC:PEGDS
Radio-labeled
900 nm
Liposome ®
PE:HYNICOB2
1200 Da PEG
OE7
1840 Da PEG
100 nm
OB16
2300 Da PEG
OB18
3680 Da PEG
Stealth SLN
Chol, PEG,
50.03 ±
Icariin
(SSLN)
Lecithin
0.90 nm
Non-Stealth
Solid Lipid
SLN (NSLN)
NP

Elimination
Half-life (of
drug) be fore
modification

62 ± 17
nm

T argeted
Stealth
Liposome ®
(T ransferin)

Stealth
Liposome ®

Siz e

120 h μg/ml

7 mg/kg

n.a.

n.a.

0.7 M lipid
(total)

BALB/c
mice

80

n.a.

n.a.

0.5 μmol/kg
0.1 μmol/kg

Humans

88

n.a.

n.a.

5 mg

Sprague–Da
wley and
Wistar rats

127

Kunming
Mice

136

Rats

135

6h

n.a.

7-8 h

43 h
28 h
15.8 ± 2.2 h
18.5 ± 4.7 h
28.0 ± 10 h
25.5 ± 2.7 h

n.a.

-

0.21 h

1.40 h

80 ± 5
nm

241.7 ± 95.3
min
5-10 min

90 ± 5
nm

211.2 ± 44.3
min
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0.82 mg h/
L
83:70 ±
19:82 μg
min/ml

3.34 mg h/L 7.46 mg/kg
814.45 ±
46.11 μg
min/ml
1121.10 ±
75.85 μg
min/ml

6 mg/kg

TABLE 2.I (continued)

Type

Name of
Produ ct

Liposomal
Doxorubici
n (L-Dox) /
Caelyx
Dendrimer
Doxorubici
n (D-Dox)
P EG45 DiCP T
P EG45 T et raCP T
P EG45 Oct aCP T

Dru g Load

Doxorubicin

C on sti tu e n ts
of
modi fi cati on

Size

P C, P EG-40carbonyldist earoylphosp
hat idylet hanola
mine

12 nm

P olylysine,
P EG1100

89 nm

DN1

FN1

Folat e-P AMAM
conjugat e,
Indomet hacin =
964.8 ± 14.96
μg/ml

Dendrimers

FN2

FN3

Indomet hacin
(int raperit oneal
Folat e-P AMAM
administ rat ion
conjugat e,
)
Indomet hacin =
1393.8 ± 21.75
μg/ml

El i mi n ati on
Hal f-l i fe
afte r
modi fi cati on

-

0.42 ± 0.07
μg h/ml

36

1786 ± 367
μg h/ml

341 ± 39 μg
h/ml

1.61 h

47.13 %ID
h/g
-

239.71 %ID
h/g

1.70 h

58.2 %ID
h/g

6.12 ± 0.78 h

125.94 ±
22.34 μg
h/ml

7.80 ± 0.15 h

127.56 ±
25.19 μg
h/ml
91.93 ±
10.35 μg
h/ml

3.09 ± 0.13 h

Folat e-P AMAM
conjugat e,
Indomet hacin =
1457.5 ± 20.28
μg/ml

Pl asma
AUC
(afte r)

19.3 ± 3.1 h

5.82 h

dia 1 μm
long

n.a.

Pl asma
AUC
(be fore )

23.6 ± 3.0 h
0.5 ± 0.1 h

100 nm
nanosphe
re
Campt ot hecin P olylysine, P EG 60 nm
dia. 500
nm
100long
nm
Folat e-P AMAM
conjugat e,
Indomet hacin =
932.0 ± 12.52
μg/ml

El i mi n ati on
Hal f-l i fe (of
dru g) be fore
modi fi cati on

8.89 ± 1.94 h

121.22 ±
1.86 μg h/ml

8.17 ± 1.63 h

166.59 ±
0.20 μg h/ml

In je cte d
Dose

Te st
S u bje cts

Re f No.

2 mg/kg
(dox equiv)

Walker 256
t umorbearing rat s

142

10 mg CP T eq./kg

BALB/c
mice

143

3.3 mg/kg
Indomet haci
n equiv.

Art hrit ic
Wist ar rat s

144

TABLE 2.I (continued)

Type

Name of
Product

DN1

FN1
Dendrimers

FN2

FN3

Drug Load

C onstitue nts
of modification

Folate-PAMAM
conjugate,
Indomethacin =
932.0 ± 12.52
μg/ml
Folate-PAMAM
conjugate,
Indomethacin =
964.8 ± 14.96
Indomethacin
μg/ml
(in inflamed
Folate-PAMAM
paw)
conjugate,
Indomethacin =
1393.8 ± 21.75
μg/ml
Folate-PAMAM
conjugate,
Indomethacin =
1457.5 ± 20.28
μg/ml

Siz e

n.a.

Elimination
Half-life (of
drug) be fore
modification

Elimination
Half-life
afte r
modification

Plasma
AUC
(afte r)

11.79 ± 2.68
h

396.44 ±
18.65 μg
h/ml

22.79 ± 3.15
h

579.01 ±
19.25 μg
h/ml

207.51 ±
15.42 μg
h/ml

5.06 ± 0.42 h

37

Plasma
AUC
(be fore )

29.92 ± 2.36
h

602.89 ±
22.18 μg
h/ml

37.08 ± 2.94
h

850.73 ±
20.59 μg
h/ml

Inje cte d
Dose

Te st
Subje cts

Re f No.

3.3 mg/kg
Indomethaci
n equiv.

Arthritic
Wistar rats
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2.4 CONCLUSIONS
Stealth engineering for DDS to prolong circulation time and maintain therapeutic levels of
drugs in blood by camouflaging the substrate from MPS has been a topic of interest over the past
50 years. From surface PEGylation to designing DNA boxes, there have been many optimistic
attempts to create the perfect DDS. This review paper describes the progression of engineering
techniques used for DDS, and the key results from in vitro, in vivo and clinical studies. Such
research has many therapeutic applications in humans including systemic cancer treatment, bone
regeneration, gene therapy, curing pathogenic infections and insulin control. It has allowed
initiation of advanced research in several vistas such as completely controllable drug delivery,
where the dose intensity, duration and instant can be precisely and monitored. An exponential
growth of such smart DDS can be predicted.
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Chapter 3
MAGNETIC STIMULUS RESPONSIVE VANCOMYCIN DDS BASED ON
CHITOSAN MICROBEADS EMBEDDED WITH MAGNETIC
NANOPARTICLES
3.1 INTRODUCTION:
In the past few decades, pharmaceutical research has progressed significantly in various
smart drug delivery systems (DDS) that are aimed at controlling dosage and drug localization.1
Traditional systemic delivery of antibiotics is not always effective in achieving minimum
inhibitory concentration (MIC) required for sustained treatment at the target site of injured
tissue, thereby requiring stronger or repetitive dosages for efficacy in preventing infection.2 The
reason for insufficient concentration is usually due to avascular nature of the injured tissue,
dissipation of drug into non-targeted tissues, dilution due to vascular circulation, or opsonisation
by Mononuclear Phagocytic System (MPS). There have been numerous approaches to enhance
pharmacokinetic efficiency and longevity of pharmaceutical products in vivo.1 A popular
method is to use a biocompatible, biodegradable DDS that allows longer bioavailability and
localization of drug at potent concentrations at the site of interest. Chitosan has been extensively
studied as a drug carrier because of positive characteristics such as biodegradability, noncytotoxicity, intracellular permeability, biocompatibility, and its ability to entrap drugs.3-5
Although these DDS prolong the lifetime and efficacy of drug compared to naked drug,
these DDS characteristically have a continuous first-order elution profile until the drug reserve
is exhausted.6 Slow degrading or non-degrading carriers such as poly-methylmethacrylate may
continue releasing antibiotics at sub therapeutic levels after the drug payload is drained,
increasing the risk of antibiotic resistance.7 Several modifications have been proposed to make
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such DDS responsive to a variety of stimuli, which would enable on-demand dosage
optimization to actual therapeutic requirement.8-10 Also, a drug boost at later time points may
increase drug elution to therapeutic levels, thereby increasing efficacy and reducing the risk of
drug-resistant bacterial strains.11
A DDS that is responsive to an exogenous stimulus of high-frequency alternating magnetic
field, for on-demand drug releases has been developed (Fig. 3.1).12 The DDS is in the form of
microbeads fabricated from chitosan, cross-linked with poly-ethylene glycol dimethacrylate
(PEGDMA) and embedded with magnetic nano-particles (MNP). As chitosan microbead itself
does not respond to an external magnetic stimuli, MNP were embedded at the time of chitosan
microbead preparation to enable the DDS to demonstrate hyperthermia phenomenon. The
antibiotic vancomycin was loaded into microspheres to study drug release profiles with and
without magnetic stimulation. A long term study was also performed via magnetic stimulation
applied to microbeads after 12 to 15 days in vitro, in which a controlled increased drug delivery
occurred even after initial first order elution profiles had been reached. This external noninvasive stimulation approach may have the benefit of using a non-invasive stimulus to
maintain the antibiotic release profile for extended durations of infection prevention.

Fig. 3.1: Conceptualized framework for the DDS responsive to external stimuli.
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3.2 MATERIALS AND METHODS:
MNP-loaded chitosan microbeads were prepared by an emulsion cross-linking method as
described below, followed by the setup used for providing magnetic stimulus.
3.2(a) Preparation of Magnetic Nanoparticle [MNP]:
The Fe3O4 MNP were made by following the non-surfactants method described by Kang et
al. 13 MNP were imaged by a Transmission Electron Microscope (Jeol JEM 1200) and the sizes
of 500 individual particles in random fields of view were measured with ImageJ. D8 Advance
(Bruker Inc.) diffractometer was used to measure x-ray diffraction (XRD) with Cu-Kα (λ =
0.15418 nm) radiation. A magnetization curve for the same samples was obtained by VSM-130
(Dexing Magnet Tech. Co.) at room temperature.
3.2(b) Preparation of Chitosan Microbead:
A modified water-oil emulsification technique reported by Jain et al was followed to make
chitosan microbeads.14 The preparation of the chitosan DDS can be divided into three phases:
(1) Preparation of chitosan solution, (2) Emulsification/cross-linking step of chitosan
microbeads, and (3) Washing stage.
In Phase 1, a solution of 4% wt. chitosan, 2% wt. MNP (Fe3O4), 1% volume glacial acetic acid
and 0.8% vancomycin was made. Then, 1g MNP was added to 46 ml DI water in a 50 ml
centrifuge tube and sonicated. The mixture was then added to 2 g chitosan (Chitopharm S) and
0.4 g vancomycin (MP Biomedicals). After that, 0.5 ml glacial acidic acid was added and the
solution was stirred well. The solution was set up on an impeller and left to stir overnight.
In Phase 2, 2 g Span 80 surfactant (Sigma Aldrich), 75 ml light mineral oil, 75 ml heavy
mineral oil (Fisher Scientific) and 15 ml PEGDMA Mn=550 (Sigma Aldrich) were combined in
a beaker. This solution was placed on a hot plate and stirred by an impeller for a few hours.
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Then, 15 ml chitosan solution from Phase 1 was injected into the mixture. The hot plate was set
to 60O C and left for 24 hr.
In the last phase, the excess oil was drained and the beads were centrifuged, followed by
thorough washing with hexane, methanol, and acetone. After the final wash, the beads were resuspended in approximately 10 ml of acetone and poured into a glass petri dish to dry.
The same process was followed without adding the Fe3O4 nanoparticles for making chitosan
microbeads without MNP. Both kind of microbeads were imaged with a Scanning Electron
Microscope (XL30 ESEM) after fixing them on a carbon tape and coating with 5 nm Au/Pd on
a sputter-coater (EMS 5502X).
3.2(c) Procedure for stimulus:
A MagneTherm instrument (nanoTherics, UK) was used to provide magnetic stimulation
(Fig. 3.2). It consists of interchangeable 9 and 17 turn coils with 10 different capacitor banks,
each of which is characterized by a specific resonant frequency and maximum magnetic flux
density. The coil is water-cooled and positioned around a sample holder. A fiber optic
thermometer (Optocon, Germany) was used for temperature measurements of media
surrounding the samples.

Fig. 3.2: Photograph of the Magnetherm equipment for magnetic stimulation.
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A preliminary temperature rise test with 5 frequency/intensity combinations was performed
and compared to determine the setting that caused the highest temperature rise in a sample of
MNP. Based on results of this test, stimulus parameters for all DDS experiments were set at
109.9 kHz/25 mT, as this setting has produced the maximum temperature rise in this test.
3.2(d) Experiments on Chitosan microbeads with magnetic nano-particles:
(i) Short term elution study: The total duration of this experiment was 8 hrs, with test groups
stimulated at 3rd, 5th and 7th hr for 30 min as shown in Fig. 3.3. The DDS was divided into 10
samples of 100 mg each, of which 5 were assigned as control (non-stimulated) and 5 as test
groups. 4 ml was added to each sample. The PBS is completely refreshed with the same volume
of fresh PBS every 1 hr.

Fig. 3.3: Short time elution study timeline of hyperthermia experiments on samples with MNP.
(ii) Long term elution study: To evaluate clinically relevant application of this DDS elution and
stimulation over a period of several days at a point when drug release is depleted or below
active concentrations, the DDS samples were placed in 4 mL PBS and media was refreshed
daily for 11 days and were then stimulated for 60 min on Day 12 and Day 15, as depicted in Fig.
3.4. The experiments consisted of 6 control (non-stimulated) and 6 test samples, each with 100
mg MNP-chitosan microbeads. 100 µl from the PBS was collected before and after stimulation
on day 12 and 15. Additional 100 µl samples were also collected on day 13 and day 16.
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Fig. 3.4: Long term elution study timeline of hyperthermia experiments on samples with MNP
(iii) General Hyperthermia Study: To investigate if the samples would exhibit a similar drug
release when treated to the same temperature increment by other means, 5 DDS samples (test
groups) were also subjected to a rapid temperature rise of 16°C in an incubator, which was the
same temperature rise observed via magnetic hyperthermia. The experimental timeline was
same as showed in Fig. 3.3. A separate batch of 5 samples was not given any stimulation and
were labelled as control groups for comparing drug elution. All samples in both groups had 100
mg microbeads in 4 ml PBS.
3.2(e) Experiments on Chitosan microbeads without MNP:
In order to demonstrate the role of MNP in aiding drug release, experiments above were
conducted on beads without MNP. In these set of experiments, there were 5 control and 5 test
samples containing 100 mg of microbeads. Due to the very fine and light nature of these beads,
complete media refreshment was not possible without pipetting out several microbeads each
time. To avoid introducing errors due to non-consistent sample weight, a slightly different
timeline was followed, as shown in Fig. 3.5. Stimulations were given at 3rd, 5th and 24th hr, each
session of 30 mins. At t = 0, 10 ml of PBS was added to all samples. Then, 120µl of the
supernatant was collected before and after the stimulation sessions.
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Fig. 3.5: Timeline of hyperthermia experiments on samples without MNP. Vertical arrows
represent sampling instances for HPLC tests.
3.2(f) Data Collection, Calibration and Analysis:
High performance liquid chromatography (Dionex UltiMate 3000 HPLC, Thermo
Scientific, Waltham, MA) was used for analyzing vancomycin amount released from the
collected supernatant. The release data between stimulated and non-stimulated groups were
analyzed by the non-parametric Mann Whitney test. The significance level for assessing
significant differences in drug elution was fixed at 5%.
3.3 RESULTS
3.3(a) MNP characterization:
The XRD (Fig. 3.6(a)) confirms the presence of Fe3O4 phase and magnetization curve (Fig.
3.6(b)) show magnetic nature of the MNP up to 1.2 T field. Size analysis of TEM imaging (Fig.
3.6(c)) revealed the size of MNP distribution to be 10.89±2.67 nm.

Fig. 3.6: (a) XRD pattern, (b) magnetization versus field curve, and (c) TEM image of Fe3O4
MNP.
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3.3(b) Chitosan microbead characterization:
The microbeads were imaged using an SEM (Fig. 3.7) and the size distribution of these particles
was 288.4 ± 62.2 µm.
(a)

(b)

Fig. 3.7: SEM image of chitosan microbeads (a) with MNP and (b) without MNP.
A Fourier Transform Infrared Spectroscopy (FTIR) for the chitosan/MNP microbeads is
shown (Fig. 3.8). The observed peaks were C-O-C Stretching(1070 cm-1), C-H rocking (1400
cm-1), Amide II (1530 cm-1), N-H Scissor (1550 cm-1), C=O (1640,1720 cm-1), C-H (2850,2920
cm-1) and N-H Stretch (3350-3280 cm-1), OH (2700-3600 cm-1). The XRD of chitosan,
vancomycin and chitosan microbeads with MNP are shown in Fig. 3.9.

Fig. 3.8: FTIR of chitosan microbead containing MNP, vancomycin and PEGDMA.
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Fig. 3.9: XRD plots of (a) vancomycin, (b) chitosan with PEGDMA and vancomycin, and (c)
chitosan with PEGDMA, vancomycin, and MNP.
3.3(c) Experiments on Chitosan microbeads with MNP:
A temperature elevation of 16ºC was recorded after each magnetic stimulation from MNP
loaded chitosan.
(i)

Short term elution study: The eluted concentration as a function of time is graphed in

Fig. 3.10, which shows a statistically significant drug increase in stimulated samples. After
stimulation at each of the 3 instances, the test groups released significantly higher amount of
vancomycin compared to control (p ≤ 0.008). In the periods when no stimulation was given, the
test groups released similar amounts of drug to control levels (p > 0.05).

Fig. 3.10: Concentration of vancomycin over time with (Stim) and without (Control) stimulation
for short term elution study with stimulation given at third, fifth and seventh hour. Data
represented is average6standard deviation. Asterisks (*) represent statistically significant
differences between stimulated and control groups, p<0.05.
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(ii)

Long term elution study: After 12 days of passive dissolution of antibiotics, vancomycin

release from microparticles dropped below theoretically effective minimum inhibitory values
against S.aureus. Magnetic stimulation of these microbeads for 30 minutes at days 12 and 15
caused an increase in vancomycin release to above the theoretically effective minimum
inhibitory concentration of 1µg/ml against S. aureus (Fig. 3.11). For both stimulation events on
Day 12 and Day 15, the test groups released statistically significant higher amounts of
vancomycin (p = 0.002). In the non-stimulation periods, there was no statistical difference in
drug elution between both groups (p > 0.05).

Fig. 3.11: Concentration of vancomycin over time with (Stim) and without (Control) stimulation
for a long term elution study with stimulus given on day 12 and day 15. Data represented is
average ± standard deviation. Asterisks (*) represent statistically significant differences between
stimulated and control groups, p<0.05.
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(iii)

General Hyperthermia Study: No significance differences were detected between both

groups (Fig. 3.12).

Fig. 3.12: Concentration of vancomycin over timewith and without stimulation in an incubator.
Data represented is average ± standard deviation. Asterisks (*) represent statistically significant
differences between stimulated and control groups, p<0.05.
3.3(d) Experiments on Chitosan microbeads without MNP:
The vancomycin concentration detected at each sampling points is shown in Fig. 3.13. There
was no statistically significant difference in drug release between magnetically stimulated and
non-stimulated MNP-free chitosan beads (p > 0.05). The temperature rise did not exceed 3ºC,
which was the normal temperature rise observed in the MagneTherm chamber when the coil is
generating a 25 mT magnetic field at 109.9 kHz, without any samples.
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Fig. 3.13: Amount of vancomycin eluted by chitosan microbeads without MNPs. Assuming 5%
significance level, the difference in vancomycin elution were not significant between test and
control groups.
3.4 DISCUSSION
The DDS developed was responsive to a high frequency magnetic field, releasing increased
amounts of antibiotics when stimulated. We were also able to boost antibiotic levels above MIC
after several days by stimulation. Magnetic excitation was chosen over other stimulation
modalities because this stimulation approach does not require any direct physical contact with
the patient and is already being used for other needed clinical external stimulations, such as
regenerating bone by stimulating external fixation devices.15 The cross-linking process
produced microbeads of the size that could be delivered through larger gauge syringes. While
general diffusion of drug occurred between these stimulations, the ability to increase release
with external, non-invasive means shows promise clinically.
XRD of the Fe3O4 MNP (Fig. 3.6(a)) show the peaks are consistent with those reported in
literature.16,17 Size of MNP produced were similar to other reported nanoparticles.16,17 The
hysteris loop of the MNP (Fig. 3.6(b)) confirms its superparamagnetic behavior. The major
peaks of chitosan (Fig. 3.9(a)), vancomycin (Fig. 3.9(b)) and MNP (Fig. 3.6(a)) are prominent
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in XRD of the chitosan-MNP microbeads (Fig. 3.9(c)), supporting the presence of these
constituents in the DDS.18,19 It was further affirmed by FTIR (Fig. 3.8) which showed amine
groups and hydroxyl groups corresponding to chitosan and vancomycin respectively. The C-OC stretching confirms the inclusion of polyethylene glycol in the DDS.

Fig. 3.14: Chemical structures of (a) chitosan, (b) vancomycin, and (c) reaction mechanism of
PEGDMA crosslinker with chitosan and vancomycin.
In this DDS, vancomycin as well as chitosan can bind to PEGDMA through Michael
addition reactions. Fig. 3.14 (a, b) show chemical structures of chitosan and vancomycin
respectively. Similar to chitosan, vancomycin has two amino groups. Those amino groups react
with the crosslinker PEGDMA as shown in Fig. 3.14 (c), in the phase 2 step of microbeads
preparation. After the reaction, some vancomycin should be immobilized via degradable ester
bond. Ester hydrolysis is known to accelerate at elevated temperature in the presence of acidic
water. The chitosan microbeads may have confined slightly acidic water from the emulsion
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procedure. Therefore, it is very likely that this conjugated ester bond was cleaved as a result of
hyperthermia, causing vancomycin release. In addition, as the crosslinked chitosan-PEG bond is
also cleaved by heat, diffusion of vancomycin could also be promoted by this stimulus.
In general hyperthermia tests on chitosan/MNP beads (Fig. 3.12), although the samples
underwent the same elevation in temperature, the absence of a significant difference in
vancomycin elution from test groups compared to test groups suggests that magnetic field is
necessary for causing response. The dependence of drug release on magnetic field was further
confirmed when chitosan microbeads without MNP were subjected to the same stimulation
parameters (Fig. 3.13) but failed to show a significant variation in elution profile of vancomycin
in comparison to control groups. It is known that on excitation with an alternating magnetic
field, magnetic nanoparticles generate and dissipate heat due to core relaxation losses.20-23 In the
chitosan/MNP DDS, the localized temperature rise around the MNP on a nano-scale is likely to
be much higher than 16ºC, which might be sufficient for cleaving the bonds. Further tests are
needed to explore the exact mechanism causing vancomycin release.
Magnetic hyperthermia has been extensively explored for smart therapeutic applications like
cancer therapy and drug delivery, leading to successful clinical trials on human subjects with
brain/prostate cancer.24,25 Also, since MNP, like magnetite, have been proven to be efficient
MRI contrast agents26-28, they facilitate drug targeting, localization and confinement.29 Some of
our preliminary tests further indicated that the DDS exhibits favorable cyto-compatibility.12
The repeated increases in release upon stimulation in the elution studies is relevant clinically
because it gives the care provider freedom to administer dosage as per each patient’s unique
needs, without intravenous procedures each time.) Ethylene-vinyl acetate copolymer polymeric
matrices loaded with insulin and MNP showed similar passive elution of active insulin as
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release of antibiotic in this DDS, with higher activity in glucose lowering after stimulus of
magnetic field.30 Finotelli et al. loaded insulin in alginate/chitosan microbeads with magnetite
nanoparticles and showed insulin release tripled in stimulated groups with respect to nonstimulated groups in response to a magnetic field.31
Katagiri and his group designed polyelectrolyte hollow multilayered shells containing dye,
coated with Fe3O4 MNP and an amphiphilic bilayer that released dye upon magnetic stimulation
which was attributed to heat-induced change in phase of amphiphile membrane, rather than any
structural fissure.32 Preliminary SEM and macroscopic observations of the DDS used in this
study suggests that stimulation does not cause damage to the structure of microbeads. This is in
contrast to some magnetically responsive DDS, such as Fe3O4/poly(allylamine) polyelectrolyte
microcapsules, that formed microcavities on the DDS surface on application of a high frequency
magnetic field and exacerbated into major ruptures with time, eluting drug in significant
amounts.33 Koppolu et al. designed MNP cores with outer multilayered shells of the
temperature-responsive polymer poly(N-isopropylacrylamaide) (PNIPAAm) and poly(D,Llactideco-glycolide) (PLGA) as carriers of both curcumin and bovine serum albumin (BSA);
while curcumin showed a sustained release profile over 13 d, BSA could be burst-released from
PNIPAAm layer by elevating temperature.34
3.5 CONCLUSION
The results demonstrated that the DDS responded to stimulus by discharging significant
amount of drug compared to control non-simulated samples. It was also observed that the DDS
did not respond to general hyperthermia, indicating that any in vivo thermal fluctuations will
not affect drug elution. The experiments further suggest that this DDS has the potential to burstrelease higher amount of drugs on multiple instances of stimulus, several hours or days apart as
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needed, and thus might enable us to maintain or control drug concentrations in the targeted
treatment location. It can aid in targeting drug directly to problem areas, preventing systemic
toxicity. The DDS also has the capability to be guided, localized and confined at the target site
by a static magnetic field35. Once at the site, drug can be released, when required, by an
external alternating magnetic field as demonstrated in this work. These features would greatly
assist clinicians in controlling drug delivery, dosage timings and local concentration to match
the clinical needs of the patient.
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Chapter 4
ELECTRIC STIMULUS RESPONSIVE CHITOSAN/MNP MICROBEADS
FOR A SMART DRUG DELIVERY SYSTEM
4.1 INTRODUCTION:
Systemic drug delivery has several setbacks like rapid flushing out of circulation and low
specificity to target site, thus usually requiring frequent invasive administration leading to
patient discomfort. Sterically sheathing the drug in a biocompatible polymer substrate helped in
remedying some of these shortcomings [1], however, such Drug Delivery System (DDS) were
characterized by an initial burst release of their therapeutic payload and a subsequent first-order
elution profile until the drug is exhausted.
Several researchers have proposed improvisations to the DDS to make the drug release
responsive to stimuli [2-4]. A variety of electric stimuli such as pH, magnetic field, ultrasound,
light etc. have been successfully demonstrated to be capable of altering the normal drug elution
profile and cause a higher amount of drug release from the DDS [2-4].
The foundation for exploring drug release by electric stimulus was laid by Zinger and Miller
who in 1984 applied 1V voltage to Polypyrrole (PPy) films loaded with glutamate to cause a
controllable higher release of the drug [5]. Weaver et al electrodeposited PPy/graphene oxide
films on glassy carbon electrodes. The films were loaded with dexamethasone, which was
released by application of a biphasic voltage pulse [6]. Besides using PPy, another common
method for electro-responsive drug release mechanisms is designing reservoirs containing the
drug load of interest. These reservoirs are sealed off with a membrane that disintegrates or
forms reversible pores when an electric current is passed through them [7-9]. Such reservoirs
are made by complicated processes involving etching and lithography, and have a height up to a
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few millimeters. Chitosan gels have also been explored for drug delivery by positioning
electrodes on either side of the gel and applying a potential difference across the gel [10-11].
This paper explores a novel method of controlling drug release by electric stimulus applied
to the DDS via silver Inter-Digitated Electrodes (IDE) printed on Polyimide substrate by an
Inkjet printer (Fig. 4.1). The IDE were measured to be only a few microns in height [12],
further enhancing their suitability as a thin, flexible implant for controllable drug release from
the DDS. The DDS is chitosan based, crosslinked with Polyethylene Glycol Dimethacrylate
(PEGDMA) and containing magnetic nanoparticles (MNP). Vancomycin was chosen as the
drug of interest. In our previous work, we established the same DDS to be responsive to
magnetic stimuli as well [13]. Either or both of these stimulation modes can be used to
administer drug dosages according to unique therapeutic requirements of each patient, without
repetitive invasive procedures to maintain potent drug concentration. Furthermore, we have
previously demonstrated this DDS can release drug with magnetic stimulation [13], thus making
it possible to use suitable stimulation modality as well as utilizing them in conjunction to
increase efficacy is possible.

Fig. 4.1: Pictorial description of vancomycin release from chitosan microbeads by an electric
stimulus
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4.2 MATERIALS AND METHODS:
4.2(a) Chitosan Microbead Preparation and Characterization:
The chitosan DDS were made by a modified water-oil emulsification method [13-14]. The
MNP and chitosan microbeads were scanned with an X-Ray Diffractometer (XRD)
(D8/Advance, Bruker Advance X-Ray solutions) with Cu-Kα radiation, λ = 0.15418 nm.
Further, the microbeads were also scanned by a Fourier Transform Infrared Spectrometer
(FTIR) (Nicolet iS 10 FTIR Spectrometer) in the mid IR range of 400-4000cm-1.
4.2(b) Preliminary Drug Delivery results using SAW resonators to apply stimulation:
In one of our initial studies [15] to explore the viability of using IDE as a stimulation
modality, we used off the shelf Surface Acoustic Wave (SAW) resonators (Model:R880,
EPCOS AG, Germany) which contain pre-designed IDE inside the cavity (Fig. 4.2).

Fig. 4.2: Exposed SAW resonator with inter-digitated electrodes encircled (inset) Portion of
interdigitated electrodes, viewed at 20x under a light microscope.
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The DDS was in form of chitosan microbeads with MNP, cross-linked with glyoxal and
containing Alizarin red S. After exposing these IDEs, the DDS samples were mixed with 10 µl
Phosphate Buffered Solution (PBS) and carefully placed inside the cavity. Electrical stimulation
was applied for 30 s. The Alizarin red S released was measured by a spectrophotometer (Model:
Synergy H1 microplate reader, BioTek US, Winooski, VT) at 350 nm. Three different
stimulation waveforms were applied to the IDE, along with control groups that did not undergo
any stimulation. The test numbers for them were labelled as follows:
Table 4.1: Different stimulation waveforms applied to microbeads in SAW resonators
Test Number

Pulse type

1

None (control)

2

20 Vpp, 1 kHz, 10% duty cycle, bipolar rectangular

3

20 Vpp, 500 Hz, 10% duty cycle, bipolar rectangular

4

20 Vpp, 1 kHz, sinusoidal

4.2(c) Printing IDE and test setup:
After demonstrating the proof-of-concept, we explored stimulating larger volume by using
IDEs to cause drug release. We adopted an approach to print IDEs on flexible substrates. A
Fujifilm DMP-2831 material deposition printer (Fujifilm Dimatix, NH) was used to print IDEs
on Polyimide (PI) tape with Silver ink. The silver ink was purchased from Novacentrix
(Metalon JS-B40HV). After printing, the PI tape was shifted from printing platen to a glass
substrate and thermally cured at 180°C to make the silver traces conductive and adhere to the
PI.
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The silver ink has a propensity to spread on PI tape, thus actual printed electrodes’ width is
wider than the width specified in design parameters. The fingers need to be reliably placed in
closest possible proximity to each other to generate a high electric field, without causing an
electric short. Several designs with different dimension were printed and tested. The layout
shown in Fig. 4.3 was observed to be optimal and yielded consistent, reliable prints each time.
This IDE pattern has a length of 35 mm and a width of 18.7 mm. Both terminals have 8 fingers
and each finger is 7.5 mm long and 0.6 mm wide, and is spaced 0.6 mm from its neighboring
electrode.

Fig. 4.3: IDE dimension and layout. All measurements are in mm
After the IDEs were cooled down, a 1” plastic tube section was affixed around the IDE with
silicon resin and left to dry for 48 hours. This step was necessary to constrain the PBS and DDS
on top of the IDE. After 48 hours, wires were attached to the IDE terminals using copper tape
(Fig. 4.4).
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Fig. 4.4: IDE setup on Polyimide substrate
The IDE are now ready to be used for stimulation. A 1Ω resistor was connected in series
with the IDE to aid in current measurement. The whole setup was connected to a signal
generator (DG4062, Rigol, USA). An oscilloscope (Tektronix TDS1001B, USA) was used to
record all requisite waveforms. The setup schematic is drawn in Fig. 4.5 and a photograph in
presented in Fig. 4.6.

Fig. 4.5: Schematic diagram for stimulating IDE
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Fig. 4.6: The complete setup connected according to the schematic in Fig. 4.5
4.2(d) Drug Delivery results using printed IDEs to apply stimulation:
In initial results to study if drug release is possible with this setup, a simple 4 min timeline
was used, as shown in Fig. 4.7. Both stimuli were 100 Hz bipolar rectangular current pulses of
250 mA for 10% duty cycle and -25 mA for 90% duty cycle, applied for 30 s to the test groups.
The control samples did not receive any stimulation. Both control and test groups had 5
samples, each sample containing 100 mg of DDS in 5 ml PBS.

Fig. 4.7: Short term timeline (4 mins) used to stimulate the DDS with printed IDEs
Following this study, we wanted to extend the timeline to span a longer duration with
electric pulses provided at a later time-point to simulate more practical in vivo scenarios
The DDS were divided into 10 samples, each weighing 100 mg. The samples were divided into
two groups of 5 samples each. One group was labeled as “test groups” which received the
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stimulation and the other group was labelled as “control groups” and did not receive any
excitation. The test timeline is showed in Fig. 4.8.

Fig. 4.8: Extended timeline with stimulation at a later timepoint
The electric stimulus given to the test groups was a bipolar rectangular current waveform of
100 Hz, with 40 mA applied for 10% duty cycle and -25 mA applied on the remaining 90%.
4.2(e) Scanning Electron Microscope Images (SEM):
The microbeads and IDEs before and after stimulation were imaged with an SEM (Nova
NanoSEM) to study the effects of stimulation on both.
4.3 RESULTS
4.3(a) Chitosan Microbead Characterization:
The XRD of MNP and chitosan microbeads are shown in Figs. 4.9 and 4.10. The
crystallographic peaks in MNP match those expected for Fe3O4 MNP and the XRD of the
chitosan confirms the integrity of MNP, vancomycin and chitosan in the final product. The
FTIR of the microbeads is shown in Fig. 4.10 along with the labelled peaks which also
correspond to those expected of chitosan [16]. The MNP had an average size of 10±2.67 nm.
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Fig. 4.9: XRD of MNP with labelled diffraction peaks (inset) Transmission Electron
Microscope image of MNP

Fig. 4.10: XRD of chitosan DDS with labelled peaks of chitosan, MNP and vancomycin (vanc)
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Fig. 4.11: FTIR spectra for chitosan microbeads with vancomycin, MNP and PEGDMA
crosslinker
4.3(b) Preliminary Drug Delivery results using SAW resonators to apply stimulation:
The absorbance measured was analyzed with a one-tailed t test. At 5% significance level,
only the bipolar rectangular pulses released a significantly higher amount of alizarin in
comparison to control. Lower frequencies were also concluded to be more efficient in inducing
elution from the substrate (Fig. 4.12).

Fig. 4.12: Absorbance endpoint measured at 350 nm for (1) control (2) 20 Vpp, 1 KHz, bipolar
rectangular (3) 20 Vpp, 500 Hz, bipolar rectangular and (4) 20 Vpp, 1 kHz, sinusoidal
The tests were also repeated on plain chitosan microbeads to ascertain the necessity of MNP
in the drug release mechanism. The absorbance measured at 350 nm (Fig. 4.13) did not show
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significant elution differences in alizarin between both groups, indicating that MNP are required
to aid drug release.

Fig. 4.13: Absorbance of alizarin measured between stimulated
4.3(c) Drug Delivery results using printed IDEs to apply stimulation:
For the 4 minutes stimulation timeline (Fig. 4.11), the test groups were found to elute a
statically significantly (p<0.05) higher amount of vancomycin in both stimulation spans (Fig.
4.14).

Fig. 4.14: Concentration of vancomycin released from DDS with (Stim) and without (Control)
stimulation. These samples followed the timeline depicted in Fig. 4.7
The microbeads that followed the extended timeline in Fig. 4.8 showed vancomycin
discharge increased by ~800% in the stimulation span (t = 40 min to t = 43min), as compared to
non-stimulated groups (Fig. 4.15).
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Fig. 4.15: Concentration of vancomycin released from DDS with (Stim) and without (Control)
stimulation. These samples followed the timeline depicted in Fig. 4.8.
The waveforms recorded during the excitation in timeline depicted in Figs. 4.8 are plotted in
Figs 4.16 and 4.17. Energy dissipated in the stimulation span for a single pulse of 10 ms was
calculated as 0.5 mJ, and 9.14 J for the total stimulation of 3 mins.

Fig. 4.16: Plot of current through setup
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Fig. 4.17: Plot of Voltage drop across setup
4.3(d) SEM Images:
The images taken for microbeads from test and control groups did not show any noticeable
surface damage, indicating that the electric stimulus is not physically damaging the beads or
causing structural disintegration (Figs. 4.18, 4.19). The average size of the microbeads was
measure at 288.4±62.2 µm.

Fig. 4.18: SEM image (350x) of Chitosan DDS before electric stimulation
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Fig. 4.19: SEM image (350x) of Chitosan DDS after electric stimulation
The control IDEs appeared smooth and undamaged after the tests. It was also noticed that
although the design width of an IDE finger was 600 µm, the silver ink tends to spread on PI tape
Fig. 4.20) and the actual printed IDEs had an average width of 783.68±52.6µm. The stimulated
IDE showed significant damage and peeling from the substrate (Fig. 4.21), owing to the
electrochemical reactions occurring between the PBS and IDE.

Fig. 4.20: SEM image of IDE that did not receive stimulation
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Fig. 4.21: SEM image of IDE after stimulation, showing widespread IDE damage at anode, with
a zoomed in section (inset)
4.4 DISCUSSION
A cross-section of the IDE on PI and glass substrates (Fig. 4.22) was considered for
simulation in COMSOL to understand the system better and attempt to explain mechanisms that
cause drug transport. Current density and expected ion migration to the electrodes were also
studied.
The migration of a charged ion in an electric field is given by the following Nernst Planck
transport equation (1):
dc
dt

+ ∇(−D∇c − zKFc∇V + cu
⃗)=R

(1)

Where
c = Concentration, D = Diffusion coefficient, z = Charge of ion, K = Ion mobility,
R = Rate of chemical reaction of z, F = Faraday constant, V = Electric potential, u = Velocity
field
A normalized dc voltage of 1V was applied to the positive terminal A and 0V to B (Fig. 4.22).
A chitosan microbead of radius 200 µm was also placed between the IDE fingers. The
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conductivity and dielectric permittivity of chitosan were approximated from [17]. The PBS was
assumed as 1M uniform mixture of only two charged ions (+1 and -1 charge) for simplicity. A
time dependent study was run for 0.1 s.

Fig. 4.22: Description of the layout built in COMSOL to study electric potential distribution,
current density and ion migration
The electric potential surface distribution is shown in Fig. 4.23. An examination of the
electric field plot in Fig. 4.24 distinctly shows the distortion of the field lines around the
chitosan microbead. The net electric force acting on the bead could also be causing poration in
the microbead’s polymeric network, further encouraging the elution of vancomycin when
electric current pulses are applied.

Fig. 4.23: Electric Potential distribution
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Fig. 4.24: Electric field arrows clearly show distortion caused by the chitosan microbead
The expected current density through the setup is plotted in Fig. 4.25. At beginning of
simulation both types of ions were uniformly distributed throughout the PBS. However at the
end of simulation at t = 0.1 s, a larger concentration of ions with charge +1 had migrated to
negative electrode while those with -1 were more concentrated at the positive electrode (Figs.
4.26, 4.27).

Fig. 4.25: Surface plot of current density through the setup
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Fig. 4.26: Concentration of positive ions at the electrodes at beginning (t = 0s) and end (t = 0.1s)
of simulation

Fig. 4.27: Concentration of negative ions at the electrodes at beginning (t = 0s) and end (t =
0.1s) of simulation
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The major electrochemical reactions between the silver electrodes and PBS are:
𝑁𝑎𝐶𝑙 → 𝑁𝑎+ + 𝐶𝑙 −

(2)

𝐴𝑔(𝑠) + 𝐶𝑙 − → 𝐴𝑔𝐶𝑙(𝑠) + 𝑒 −

(3)

𝐻2 𝑂 → 𝐻 + + 𝑂𝐻 −

(4)

Reaction at Anode: 𝐴𝑔 → 𝐴𝑔+ + 𝑒 −

(5)

Reaction at cathode: 2𝐻 + + 2𝑒 − → 𝐻2

(6)

These reactions are the primary cause of electrode degradation and formation of bubbles as seen
in Fig. 4.28.

Fig. 4.28: IDEs after stimulation showing degraded fingers and hydrogen bubbles
A plausible explanation of drug release could be that chitosan, being a cationic molecule
due to the acidic condition during preparation is neutralizing as the pH increases. The localized
high pH is being generated at the cathode surface by the reaction in Eqn 4, which leads to the
acid-base reaction of chitosan:
𝐶ℎ𝑖𝑡 − 𝑁𝐻3+ + 𝑂𝐻 − → 𝐶ℎ𝑖𝑡 − 𝑁𝐻2 + 𝐻2 𝑂

(7)

This de-protonation reaction of the chitosan amine group in Eq 7 is likely changing the polymer
chain interaction and the microstructure of polymer network inside the particle, accelerating the
96

diffusion of vancomycin. Temperature change caused by the flow of current could also be
promoting hydrolysis of the chemically conjugated vancomycin from the PEG crosslinker [13].
4.5 CONCLUSION
This paper has laid the groundwork for using Inkjet printing technology to design
inexpensive, flexible, thin and implantable substrates for providing electric pulses to a DDS and
causing a higher release of drug as a response. The amount of vancomycin eluted from DDS
was significantly (p < 0.05) boosted by excitation. A future challenge is to fabricate inert
electrodes that do not degrade and are capable of providing sustainable and repeatable
stimulation separated by hours, or even days.
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Chapter 5
CONCLUSIONS AND FUTURE DIRECTIONS
5.1

KEY RESULTS

The outcomes of this research can be summarized as follows:
1. We were able to design a drug delivery system (DDS) that is sensitive to both electric and
magnetic fields. The DDS displays a burst release when excited, but follows a profile
similar to the non-stimulated groups otherwise. For magnetic stimulation, we applied 25
mT, 100 Hz to the samples for at least 30 mins, but not greater than 60 mins. A bipolar
rectangular pulse waveform of electric current at 100 Hz and several milli-amperes was
applied for 30 – 180 sec to the DDS for electric stimulation. A healthcare provider could
choose either of these stimuli as deemed necessary, or even use them in conjunction to
maximize release.
2. In the studies involving magnetic hyperthermia, the DDS was stimulated multiple times
over a period of several hours or several days. The drug release observed from test groups
was incremented by as much as 200% in the stimulation period. The magnetic field was also
able to boost drug release above Minimum Inhibitory Concentration even 16 days after
regular elution from the DDS, proving that this substrate is also functional over longer
intervals that are more clinically relevant. Electric stimulation was capable of triggering a
higher drug discharge by ~800% above the normal amount discharged without any
excitation.
3. We also described a novel approach of applying electric pulses to the IDE by printed silver
inter-digitated electrodes on polyimide tape. This substrate is flexible, thin (< 2µm),
inexpensive and does not require complicated fabrication processes like etching or
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photolithography. The overall ease of designing IDE permits the flexibility to of quick redesigning according to the desired implant site type.
5.2 FUTURE RESEARCH DIRECTIONS
1. Although our preliminary in vivo studies (appendix) indicated the DDS is biocompatible,
the impact of magnetic stimulation on drug release could not be determined to be as
pronounced as in vitro. A future direction of this research would be to do more detailed
studies and characterize the DDS performance in vivo.
2. The IDE setup used for electric stimulation can be extended to be wirelessly powered,
making it a fully implantable device. As described in Chapter 4, the IDEs tend to degrade
after stimulation due to electrochemical corrosion occurring at the silver anode. Formulating
Gold or Platinum nanoparticle inks can be explored for printing instead.
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APPENDIX
A.1: Flowchart for Chitosan/MNP/vancomycin preparation
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A.2: Flowchart for stimulation tests
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A.3: Flowchart showing procedure to print IDEs on PI tape
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A.4: MATLAB® code to analyze voltage and current waveforms
%% READ DATA FROM EXCEL SHEET
dt = xlsread('C:\Users\mhapatra\Dropbox\Work\2018\March 2018\IEEE J\Waveforms\Waveform2\T0000.csv');
x = dt(:,1)*1000; % convert x axis to ms scale
ch1 = dt(:,2); % read voltage data
ch2 = dt(:,4)*1000; % read current, convert to mA
%% VOLTAGE
figure(1)
plot(x,ch1)
title('Voltage before filter')
figure(2)
windowWidth = 5; % to decrease harmonics
polynomialOrder = 3;
smoothY_V = sgolayfilt(ch1, polynomialOrder, windowWidth);
plot(x,smoothY_V+.1)
xlabel('time(ms)')
ylabel('Voltage')
title('Voltage after filter')
%% CURRENT
figure(3)
plot(x,ch2)
title('Current before filter')
figure(4)
windowWidth =39;
polynomialOrder = 3;
smoothY_I = sgolayfilt(ch2, polynomialOrder, windowWidth);
plot(x,smoothY_I)
xlabel('time(ms)')
ylabel('Current')
title('Current after filter')
pw= 0;
for i = 1:size(ch1)
pw = ch1(i)*smoothY_I(i);
end
mj = pw*0.04;

% Calculate total energy in observed waveform (4 pulses)

mj_single_pulse = mj/4; % energy in single pulse
no_of_pulse = 3*60/0.01; % calculate number of pulses in 3 min
% (total stimulation duration)
mJ-stim = no_of_pulse*mj_single_pulse % total energy spent in stimulation
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A.5: Sample code of Wilcox’s test in R for comparing vancomycin elution®
Control_1  c(307.78,362.22,119.20,126.21,141.53,186.36,268.49,604.48)
Stim_1  c(139.78,221.31,193.90,183.66,173.38,133.62,99.04,237.97)
wilcox.test(Control_1, Stim_1)
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A.6: Model Parameters used for simulation in COMSOL®

Fig. A.6.1: 2D model drawn for simulation
Table A.6.1: Dimensions of the various components in the model in Fig. A.6.1
Glass
Polyimide tape (PI)
Phosphate Buffered Solution
(PBS)
Chitosan microbead

3.6mm x 1.1mm
3.6mm x 0.5 mm
3.6mm x 2mm
0.1 mm radius

Table A.6.2: Material properties used for simulation

PBS (Phosphate
Buffered Solution)
Polyimide
Glass
Chitosan

Relative
permittivity
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Electrical Conductivity

Source

0.01

[1]

3.4
4.7
3.94

6.7e-14
1e-13
3.4e-17

COMSOL® Inbuilt material
COMSOL® Inbuilt material
[2]

[1]

Supplementary Information for Lab on a Chip, 2013

[2]

C.G.A. Lima et al., “DC conductivity and dielectric permittivity of collagen–chitosan
films”, Materials Chemistry and Physics, vol. 99, pp. 284-288, 2006
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